var title_f28_21_29008="TTTS2";
var content_f28_21_29008=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F76957&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F76957&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    TTTS2",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Polyhydramnios in the recipient's sac with a deepest vertical pocket of 12.66 cm at approximately 22 weeks of gestation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Kenneth J Moise, Jr, MD &amp; Anthony Johnson, DO.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_21_29008=[""].join("\n");
var outline_f28_21_29008=null;
var title_f28_21_29009="Calculator: Lean body weight (adult male)";
var content_f28_21_29009=[" <div id=\"topicText\">",
"  <div id=\"mc3k\">",
"   <form action=\"\" id=\"LeanBodyWgtM_form\" name=\"LeanBodyWgtM_form\" onkeydown=\"clrResults();\" onkeypress=\"return validNumberField(event);\" onkeyup=\"LeanBodyWgtM_fx();\" onsubmit=\"return false;\">",
"    <table cellpadding=\"4\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"100%\">",
"     <tr>",
"      <td bgcolor=\"#eeeeee\" width=\"1%\">",
"       <br/>",
"      </td>",
"      <td align=\"left\" bgcolor=\"#eeeeee\">",
"       <span class=\"medCalcFontTitleBox\">",
"        Calculator: Lean body weight (adult male)",
"       </span>",
"      </td>",
"     </tr>",
"    </table>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <center>",
"     <div id=\"calc_equation\">",
"      <table cellpadding=\"10\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\">",
"       <tr>",
"        <td align=\"left\" bgcolor=\"#6c9a9c\">",
"         <span class=\"medCalcFontFormuli\">",
"          LBW[kg] = (9270 * TotalBodyWeight[kg]) / (6680 + (216 * BMI[kg/m",
"          <sup>",
"           2",
"          </sup>",
"          ]))",
"         </span>",
"        </td>",
"       </tr>",
"      </table>",
"      <br/>",
"      &nbsp;",
"      <br/>",
"     </div>",
"    </center>",
"    <div id=\"calc_main\">",
"     <center>",
"      <table cellpadding=\"6\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"95%\">",
"       <tr>",
"        <td align=\"right\" width=\"50%\">",
"         <center>",
"          <span class=\"medCalcFontIO\">",
"           Input:",
"          </span>",
"          <br/>",
"          &nbsp;",
"          <br/>",
"          <table cellpadding=\"3\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\">",
"           <tr>",
"            <td align=\"right\" width=\"42%\">",
"             <span class=\"medCalcFontOneBold\">",
"              Total Body Weight",
"             </span>",
"            </td>",
"            <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"             &nbsp;",
"             <input name=\"Total_Body_Weight_param\" onblur=\"LeanBodyWgtM_fx(); minMaxCheck();\" onchange=\"LeanBodyWgtM_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"            </td>",
"            <td align=\"left\" valign=\"top\" width=\"115\">",
"             <select class=\"medCalcFontSelect\" name=\"Total_Body_Weight_unit\" onchange=\"LeanBodyWgtM_fx();\" style=\"width:105px;\">",
"              <option selected=\"selected\" value=\"1|0|kg\">",
"               kg",
"              </option>",
"              <option value=\"0.45359237|0|lb\">",
"               lb",
"              </option>",
"             </select>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"right\" width=\"42%\">",
"             <span class=\"medCalcFontOneBold\">",
"              Height",
"             </span>",
"            </td>",
"            <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"             &nbsp;",
"             <input name=\"Height_param\" onblur=\"LeanBodyWgtM_fx(); minMaxCheck();\" onchange=\"LeanBodyWgtM_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"            </td>",
"            <td align=\"left\" valign=\"top\" width=\"115\">",
"             <select class=\"medCalcFontSelect\" name=\"Height_unit\" onchange=\"LeanBodyWgtM_fx();\" style=\"width:105px;\">",
"              <option selected=\"selected\" value=\"1|0|cm\">",
"               cm",
"              </option>",
"              <option value=\"2.54|0|in\">",
"               in",
"              </option>",
"              <option value=\"100|0|m\">",
"               m",
"              </option>",
"             </select>",
"            </td>",
"           </tr>",
"          </table>",
"         </center>",
"        </td>",
"        <td align=\"left\" bgcolor=\"#eeeeee\">",
"         <center>",
"          <span class=\"medCalcFontIO\">",
"           Results:",
"          </span>",
"          <br/>",
"          &nbsp;",
"          <br/>",
"          <table bgcolor=\"#eeeeee\" cellspacing=\"4\" summary=\"MedCalc 3000 Table\">",
"           <tr>",
"            <td align=\"right\">",
"             <span class=\"medCalcFontOneBold\">",
"              LBW",
"             </span>",
"            </td>",
"            <td nowrap=\"nowrap\" valign=\"top\">",
"             &nbsp;",
"             <input name=\"LBW_param\" onfocus=\"blur();\" size=\"6\" type=\"text\"/>",
"            </td>",
"            <td valign=\"top\">",
"             <span class=\"medCalcFontOne\">",
"              <select class=\"medCalcFontSelect\" name=\"LBW_unit\" onchange=\"LeanBodyWgtM_fx();\" style=\"width:105px;\">",
"               <option selected=\"selected\" value=\"1|0|kg\">",
"                kg",
"               </option>",
"               <option value=\"0.45359237|0|lb\">",
"                lb",
"               </option>",
"              </select>",
"             </span>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td colspan=\"3\">",
"             &nbsp;",
"             <br/>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"center\" colspan=\"3\">",
"             <span class=\"medCalcFontOneBold\">",
"              Decimal Precision:",
"             </span>",
"             <select class=\"medCalcFontSelect\" name=\"decpts\" onchange=\"LeanBodyWgtM_fx();\">",
"              <option>",
"               0",
"              </option>",
"              <option>",
"               1",
"              </option>",
"              <option selected=\"selected\">",
"               2",
"              </option>",
"              <option>",
"               3",
"              </option>",
"             </select>",
"            </td>",
"           </tr>",
"          </table>",
"         </center>",
"         <br/>",
"         &nbsp;",
"         <br/>",
"         <center>",
"          <span class=\"medCalcFontOne\">",
"           <input name=\"reset\" type=\"reset\" value=\"Reset form\"/>",
"          </span>",
"         </center>",
"        </td>",
"       </tr>",
"      </table>",
"     </center>",
"    </div>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div id=\"calc_hints\">",
"     <span class=\"medCalcFontOne\">",
"     </span>",
"    </div>",
"    <div id=\"calc_notes\">",
"     <span class=\"medCalcFontOneBold\">",
"      Notes",
"     </span>",
"     <ul class=\"medCalcFontOne\">",
"      <li>",
"       The formula depicted, which is based on gender, total body weight, and height, can be used to estimate LBW for adult males who are of normal weight or obese.",
"      </li>",
"      <li>",
"       This calculation is not applicable to individuals with abnormal body water composition (eg, fluid overload).",
"      </li>",
"      <li>",
"       This calculator is not validated in individuals at extremes of height, those with highly muscular builds or in underweight individuals.",
"      </li>",
"      <li>",
"       The equation on which the calculator was based was derived from data on a population of individuals with bodyweights up to 216.5 kg  or body mass index (BMI) up to 69.9 kg/m",
"       <sup>",
"        2",
"       </sup>",
"       , but was not validated in individuals weighing greater than 131.7 kg or with BMI over 38.4 kg/m",
"       <sup>",
"        2",
"       </sup>",
"       .",
"      </li>",
"      <li>",
"       A separate calculator is available for estimating ideal body weight (method of Devine) and adjusted dosing weight.",
"      </li>",
"     </ul>",
"    </div>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div id=\"calc_refs\">",
"     <span class=\"medCalcFontRef\">",
"      <b>",
"       References",
"      </b>",
"     </span>",
"     <ol>",
"      <li>",
"       <span class=\"medCalcFontRef\">",
"        Janmahasatian S, Duffull SB, Ash S, et. al. Quantification of lean bodyweight.",
"        <i>",
"         Clin Pharmacokinet",
"        </i>",
"        . 2005;44(10):1051-65.",
"       </span>",
"      </li>",
"     </ol>",
"    </div>",
"   </form>",
"  </div>",
" </div>",
" <div id=\"topicAgreement\">",
"  Use of UpToDate is subject to the",
"  <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"   Subscription and License Agreement",
"  </a>",
"  .",
" </div>",
" <div id=\"printDisclaimer\">",
"  Information on this page may not appear correctly if printed.",
" </div>",
" <div id=\"disclaimerCalculator\">",
"  <div class=\"medCalcFontTwo\">",
"   <p class=\"header\">",
"    Legal Notices and Disclaimer",
"   </p>",
"   <p>",
"    All information contained in and produced by the MedCalc 3000 system is provided",
"			for educational purposes only. This information should not be used for the diagnosis or treatment",
"			of any health problem or disease.",
"    <b>",
"     THIS INFORMATION IS NOT INTENDED TO REPLACE CLINICAL JUDGMENT OR",
"			GUIDE INDIVIDUAL PATIENT CARE IN ANY MANNER.",
"    </b>",
"    <a class=\"medCalcDisclaimerLink\" href=\"./med-calc-disclaimer\">",
"     Click here for",
"				full notice and disclaimer.",
"    </a>",
"   </p>",
"   <p class=\"copy\">",
"    MedCalc 3000 is Copyright &copy; 1998-2013 Foundation Internet Services",
"   </p>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_21_29009=[" ",
"",
"",
"function log(i){",
"return Math.log(i) * Math.LOG10E;   ",
"}",
"",
"function ln(i){",
"return Math.log(i);",
"}",
"",
"function sq(i){",
"return i * i;",
"}",
"",
"function sqr(i){",
"return Math.sqrt(i);",
"}",
"",
"",
"function power(x,y){",
"return Math.pow(x,y);",
"}",
"",
"function eTo(x){",
"return Math.exp(x);",
"}",
"",
"",
"function fixDP(r, dps) {",
"if (isNaN(r)) return \"NaN\";",
"var msign = '';",
"if (r < 0) msign = '-';",
"x = Math.abs(r);",
"if (x > Math.pow(10, 21)) return msign + x.toString();",
"var m = Math.round(x * Math.pow(10, dps)).toString();",
"if (dps == 0) return msign + m;",
"while (m.length <= dps) m = \"0\" + m;",
"return msign + m.substring(0, m.length - dps) + \".\" + m.substring(m.length - dps);",
"}",
"",
"function alertNaN(){",
"alert('This field is improperly formatted. You may only input the digits 0-9 and a decimal point.');  ",
"doCalc = false; ",
"clrResults();",
"}",
"",
"",
"function validNumberField(event) {",
"var field = event.target;",
"",
"if(field && field != 'undefined' && field.attributes.type.nodeValue && (field.attributes.type.nodeValue == 'number')) {",
"var val = field.value;",
"var charCode = event.charCode;",
"var key = String.fromCharCode(charCode);",
"",
"if(charCode == 0) {",
"return true;",
"}",
"",
"if(key == ' ') {",
"alert('Numeric field cannot contain spaces.');",
"return false;",
"}	",
"		",
"if(val.length == 0) {",
"if(key == '+') { return true; }",
"if(key == '-') { return true; }	",
"if(key == '.') { return true; }",
"}",
"		",
"if(key == '.') { return validFloat(val, key); }",
"",
"if(isNaN(parseInt(key))) {",
"alertNaN();",
"return false;",
"}",
"	",
"return validFloat(val, key);",
"}",
"return true;",
"}",
"",
"",
"function validFloat(val, key) {",
"var currentVal = parseFloat(val + key);",
"if(isNaN(val + key) || isNaN(currentVal)) {",
"alertNaN();",
"}",
"return true;",
"}",
"",
"var currenttimeout;",
"",
"",
"var calctxt = ''; ",
"var xmltxt = ''; ",
"var htmtxt = ''; ",
"",
"",
"",
"function LeanBodyWgtM_fx() {",
"",
"currenttimeout = self.setTimeout('minMaxCheck();', 2000);",
"",
"with(document.LeanBodyWgtM_form){",
"",
"",
"doCalc = true;",
"param_value = parseFloat(Total_Body_Weight_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = Total_Body_Weight_unit.options[Total_Body_Weight_unit.selectedIndex].value.split('|');",
"Total_Body_Weight = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"param_value = parseFloat(Height_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = Height_unit.options[Height_unit.selectedIndex].value.split('|');",
"Height = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"dp = decpts.options[decpts.selectedIndex].text;",
"BMI =  Total_Body_Weight / sq(Height / 100);",
"",
"LBW =  (9270 * Total_Body_Weight) / (6680 + (216 * BMI));",
"",
"unit_parts = LBW_unit.options[LBW_unit.selectedIndex].value.split('|');",
"if (doCalc) LBW_param.value = fixDP((LBW - parseFloat(unit_parts[1])) / parseFloat(unit_parts[0]), dp);",
"",
"",
"",
"",
"",
"}",
"",
"}",
"",
"function minMaxCheck(){",
"",
"if (currenttimeout) self.clearTimeout(currenttimeout);",
"",
"with(document.LeanBodyWgtM_form){",
"",
"if (Total_Body_Weight_param.value && isNaN(Total_Body_Weight_param.value)){ Total_Body_Weight_param.value = ''; alertNaN(); }",
"if (Total_Body_Weight_param.value && Total_Body_Weight < 47) {",
"Total_Body_Weight = 0;",
"Total_Body_Weight_param.value = \"\";",
"clrResults();",
"doCalc = false;",
"alert(\"The minimum value for Total Body Weight is 47 kg.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"if (Height_param.value && isNaN(Height_param.value)){ Height_param.value = ''; alertNaN(); }",
"if (Height_param.value && Height < 137) {",
"Height = 0;",
"Height_param.value = \"\";",
"clrResults();",
"doCalc = false;",
"alert(\"The minimum value for Height is 137 cm.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"if (Height_param.value && Height > 244) {",
"Height_param.value = \"\";",
"clrResults();",
"Height = 0;",
"doCalc = false;",
"alert(\"The maximum value for Height is 244 cm.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"",
"",
"}",
"",
"}",
"",
"",
"function clrResults(){",
"",
"if (currenttimeout) self.clearTimeout(currenttimeout);",
"",
"with(document.LeanBodyWgtM_form){",
"",
"LBW_param.value = '';",
"",
"",
"}",
"",
"}",
"",
"",
"",
"",
"",
"",
"",
"",
"",
"",
"",
""].join("\n");
var outline_f28_21_29009=null;
var title_f28_21_29010="Laparoscopic surgery PI";
var content_f28_21_29010=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F56022&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F56022&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 500px\">",
"   <div class=\"ttl\">",
"    Laparoscopic surgery (gallbladder removal)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 480px; height: 622px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Laparoscopic surgery can be used to remove the gallbladder or the uterus, or to do lots of other different procedures. In this example, the gallbladder is being removed.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_21_29010=[""].join("\n");
var outline_f28_21_29010=null;
var title_f28_21_29011="Contact derm face";
var content_f28_21_29011=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F52903&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F52903&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Contact dermatitis involving the facial and periorbital skin",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_21_29011=[""].join("\n");
var outline_f28_21_29011=null;
var title_f28_21_29012="Sapropterin: Drug information";
var content_f28_21_29012=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Sapropterin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?10/37/10836?source=see_link\">",
"    see \"Sapropterin: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/9/31892?source=see_link\">",
"    see \"Sapropterin: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F5568566\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Kuvan&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F5568570\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Enzyme Cofactor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F5568660\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      PKU:",
"     </b>",
"     Oral: Initial: 10 mg/kg once daily; adjust after 1 month based on blood phenylalanine levels (if phenylalanine levels do not decrease from baseline, increase dose to 20 mg/kg once daily); discontinue if phenylalanine levels do not decrease after 1 month of treatment at 20 mg/kg/day (nonresponder). Maintenance range: 5-20 mg/kg once daily",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F5568659\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/9/31892?source=see_link\">",
"      see \"Sapropterin: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      PKU:",
"     </b>",
"     Children &ge;4 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F5568661\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F5568667\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet, oral, as dihydrochloride:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Kuvan&trade;: 100 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F5568568\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F5568663\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer with food, preferably at the same time each day. Dissolve tablets in 120-240 mL (4-8 oz) water or apple juice. May crush or stir to aid in dissolution. Take within 15 minutes of dissolution. Tablets may not dissolve completely; rinse remaining tablet residue (with more water or apple juice) and drink.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F5568571\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adjunct to dietary management in the treatment of tetrahydrobiopterin (BH4) responsive phenylketonuria (PKU)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F5568565\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Sapropterin may be confused with cyproterone",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F5568581\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Headache (15%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Rhinorrhea (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Diarrhea (8%), vomiting (8%), nausea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Bruising  (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hematologic: Neutropenia (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Pharyngolaryngeal pain (10%), cough (7%), nasal congestion (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% (Limited to important or life-threatening): Abdominal pain, agitation, appetite decreased, arthralgia, bleeding (postprocedural), dizziness, fatigue, fever, flatulence, gastritis, gastrointestinal bleeding, GGT increased, hyper-reflexia, irritability, MI, over stimulation, peripheral edema, polyuria, rash, respiratory failure, seizure, seizure exacerbation, thrombocytopenia, tremor, upper respiratory tract infection",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F5568576\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no contraindications listed in the manufacturer&rsquo;s labeling",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F5568577\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Allergic reaction: Although severe allergic reactions were not observed in clinical trials, do not administer to patients with allergy to any component of the formulation. Patients with mild-to-moderate allergy (eg, rash) should be evaluated for risk versus benefit prior to continuing therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hepatic impairment: Has not been studied in patients with hepatic impairment. Monitor carefully; hepatic damage has been associated with impaired phenylalanine metabolism.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Phenylketonuria: Phenylalanine levels should be monitored and maintained within the target range during sapropterin treatment. Low levels of phenylalanine are associated with catabolism and protein breakdown. Dietary management of phenylalanine intake is required to ensure nutritional balance and adequate phenylalanine control.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Renal impairment: Has not been studied in patients with renal impairment; use with caution.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Folic acid antagonists: Folic acid antagonists (eg, methotrexate) may decrease tetrahydrobiopterin (BH4) levels via dihydropteridine reductase enzyme inhibition.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Levodopa: In sapropterin clinical studies for a non-PKU use, seizure, over stimulation, and irritability were reported in patients also receiving levodopa; use caution.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; PDE-5 inhibitors: Use with caution with medications that affect nitric oxide-mediated vasorelaxation, including PDE-5 inhibitors (eg, sildenafil, tadalafil, vardenafil); additive effect may lead to hypotension. Sapropterin use has not been evaluated in combination with PDE-5 inhibitors.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Nonresponders: Response to sapropterin treatment is established through treatment (cannot be predetermined by lab testing). Patients whose phenylalanine levels do not decrease after treatment at 20 mg/kg/day for 1 month are considered nonresponders.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Pediatrics: Safety and efficacy have not been established in children &lt;4 years of age.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300027\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F5568645\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Levodopa: Sapropterin may enhance the adverse/toxic effect of Levodopa.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrexate: May decrease the serum concentration of Sapropterin. Specifically, methotrexate may decrease tissue concentrations of tetrahydrobiopterin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: Sapropterin may enhance the hypotensive effect of Phosphodiesterase 5 Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PRALAtrexate: May decrease the serum concentration of Sapropterin. Specifically, pralatrexate may decrease tissue concentrations of tetrahydrobiopterin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F13851498\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food: Food increases absorption of sapropterin. Management: Take with food to increase absorption. Maintain adherence to a phenylalanine-restricted diet.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F5568572\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F5568573\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Statistically significant teratogenic effects were not observed in animal studies; however, there are no adequate and well-controlled studies in pregnant women. High levels of maternal phenylalanine are associated with congenital heart disease, developmental delay, facial dysmorphism, learning difficulties, and microcephaly. Phenylalanine concentrations should be normalized prior to conception and dietary control with proper supplementation are recommended during pregnancy. Some clinicians recommend that dietary control be achieved for at least 4 weeks prior to conception; however, studies suggest that as long as control is achieved by 10 weeks of pregnancy, teratogenic effects of untreated maternal phenylketonuria can be decreased. The effects of sapropterin on pregnancy have not been determined. Pregnant women exposed to sapropterin are encouraged to enroll in the Kuvan&trade; pregnancy registry.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F5568574\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F5568575\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if sapropterin is found in breast milk. Phenylalanine and tyrosine are natural components of human milk and are amino acids required for normal development. The effects of sapropterin have not been determined.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F5568662\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Patients should maintain adherence to a phenylalanine-restricted diet. Take with food to increase absorption.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16321796\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet,Dispersible",
"     </b>",
"     (Kuvan Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (120): $4557.60",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F5568665\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood phenylalanine levels (baseline, after 1 week of treatment, periodically for first month, regularly thereafter); children may require more frequent monitoring",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F10961933\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Kuvan (BE, CH, CL, CZ, DK, EE, FR, GB, HN, IE, IL, NL, NO, PT, SE, TW)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F5568650\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Sapropterin is a synthetic form of the cofactor BH4 (tetrahydrobiopterin) for the enzyme phenylalanine hydroxylase (PAH). PAH hydroxylates phenylalanine to form tyrosine. BH4 activates residual PAH enzyme, improving normal phenylalanine metabolism and decreasing phenylalanine levels in sapropterin responders.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F5568652\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Onset of action: Within 24 hours; maximum effect: 1-2 months",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Duration: 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: Absorption is enhanced when administered with food (high fat/high calorie)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: ~7 hours (range: 4-17 hours)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Burton BK, Grange DK, Milanowski A, et al, &ldquo;The Response of Patients With Phenylketonuria and Elevated Serum Phenylalanine to Treatment With Oral Sapropterin Dihydrochloride (6R-Tetrahydrobiopterin): A Phase II, Multicentre, Open-Label, Screening Study,&rdquo;",
"      <i>",
"       J Inherit Metab Dis",
"      </i>",
"      , 2007, 30(5):700-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/21/29012/abstract-text/17846916/pubmed\" id=\"17846916\" target=\"_blank\">",
"        17846916",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Koch R, Hanley W, Levy H, et al, &ldquo;The Maternal Phenylketonuria International Study: 1984-2002,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2003, 112(6 Pt 2):1523-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/21/29012/abstract-text/14654658/pubmed\" id=\"14654658\" target=\"_blank\">",
"        14654658",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Levy H, Burton B, Cederbaum S, et al, &ldquo;Recommendations for Evaluation of Responsiveness to Tetrahydrobiopterin (BH4) in Phenylketonuria and its Use in Treatment,&rdquo;",
"      <i>",
"       Mol Genet Metab",
"      </i>",
"      , 2007, 92(4):287-291.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/21/29012/abstract-text/18036498/pubmed\" id=\"18036498\" target=\"_blank\">",
"        18036498",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Levy HL, Milanowski A, Chakrapani A, et al, &ldquo;Efficacy of Sapropterin Dihydrochloride (Tetrahydrobiopterin, 6R-BH4) for Reduction of Phenylalanine Concentration in Patients With Phenylketonuria: A Phase III Randomised Placebo-Controlled Study,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2007, 370(9586):504-10.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/21/29012/abstract-text/17693179/pubmed\" id=\"17693179\" target=\"_blank\">",
"        17693179",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Maillot F, Cook P, Lilburn M, et al, &ldquo;A Practical Approach to Maternal Phenylketonuria Management,&rdquo;",
"      <i>",
"       J Inherit Metab Dis",
"      </i>",
"      , 2007, 30(2):198-201.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9484 Version 30.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-180.241.123.62-6A9128D992-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_21_29012=[""].join("\n");
var outline_f28_21_29012=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5568566\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5568570\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5568660\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5568659\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5568661\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5568667\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5568568\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5568663\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5568571\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5568565\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5568581\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5568576\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5568577\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300027\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5568645\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13851498\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5568572\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5568573\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5568574\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5568575\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5568662\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16321796\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5568665\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10961933\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5568650\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5568652\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9484\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9484|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?10/37/10836?source=related_link\">",
"      Sapropterin: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/9/31892?source=related_link\">",
"      Sapropterin: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_21_29013="Depression treatment options for adolescents";
var content_f28_21_29013=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Depression treatment options for adolescents (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?28/21/29013/contributors\">",
"       Authors",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/21/29013/contributors\" id=\"au6787\">",
"       C Scott Moreland, DO",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/21/29013/contributors\" id=\"au4728\">",
"       Liza Bonin, PhD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?28/21/29013/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/21/29013/contributors\" id=\"se462\">",
"       Amy B Middleman, MD, MPH, MS Ed",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?28/21/29013/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/21/29013/contributors\" id=\"de3194\">",
"       David Solomon, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?28/21/29013?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      DEPRESSION OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Depression is a treatable condition. Psychological treatments (psychotherapy), drug therapy, and other measures can alleviate symptoms and help adolescents to succeed in school, develop and maintain healthy relationships, and feel more self-confident.",
"    </p>",
"    <p>",
"     This topic review discusses the treatment options available for adolescents with depression. The causes, symptoms, and diagnosis of depression are discussed separately. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?13/6/13413?source=see_link\">",
"      \"Patient information: Depression in adolescents (Beyond the Basics)\"",
"     </a>",
"     .) Parents who are unsure if their adolescent is depressed should read that topic review first.",
"    </p>",
"    <p>",
"     Topic reviews about depression in adults are also available. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?19/41/20116?source=see_link\">",
"      \"Patient information: Depression in adults (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/24/21894?source=see_link\">",
"      \"Patient information: Depression treatment options for adults (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      STEP ONE: EDUCATION",
"     </span>",
"    </p>",
"    <p>",
"     In adolescents, treatment for depression is most successful when the parents are involved. Learning about depression is an important component of depression treatment. Family education is also important before decisions are made about the adolescent's treatment plan.",
"    </p>",
"    <p>",
"     Understanding how depression affects the teen's mood, thoughts, body, and behavior can help the adolescent and his or her family in several ways:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Family members can learn about the symptoms of depression and how these symptoms impact the teen's relationships with friends and family, willingness to attend school, and ability to complete school work.",
"      </li>",
"      <li>",
"       Family members can learn how to recognize if the adolescent's depressive symptoms are recurring or coming back.",
"      </li>",
"      <li>",
"       Other family members might be able to identify their own depressive symptoms and need for treatment.",
"      </li>",
"      <li>",
"       Family members can learn how to help the teen with depression. It is important to clarify the role of parents, other family members, and teachers in the teen's treatment and recovery.",
"      </li>",
"      <li>",
"       Family members can learn how to make the environment safer for depressed adolescents. For example, the need to limit access to certain items (eg, prescription medications, weapons) should be discussed.",
"      </li>",
"      <li>",
"       Family members can learn about the treatment options that are available to treat depression, including the pros and cons of various treatment options, so that they can make well informed decisions.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      DEPRESSION TREATMENT OPTIONS",
"     </span>",
"    </p>",
"    <p>",
"     Major depression is the medical term for depression that meets particular criteria. A person can have mild, moderate, or severe major depression. Adolescents with mild or moderate depression are usually treated with counseling alone. If the depressive symptoms do not begin to improve within 6 to 12 weeks, or if symptoms worsen, an antidepressant medication may be recommended.",
"    </p>",
"    <p>",
"     Adolescents with severe depression generally require psychological treatment, such as cognitive behavioral therapy (CBT) or interpersonal psychotherapy, in addition to one or more medications. Treatment with medication and an evidence-based psychological treatment (ie, CBT or interpersonal psychotherapy) increases the likelihood of improved symptoms and relationships with family and friends; it can also improve self-confidence and the ability to cope effectively.",
"    </p>",
"    <p>",
"     Compared with adults, there are fewer high quality studies of treatment for adolescent depression [",
"     <a class=\"abstract\" href=\"UTD.htm?28/21/29013/abstract/1-3\">",
"      1-3",
"     </a>",
"     ]. Current practice guidelines for treating adolescent depression are based upon a combination of data from studies of depressed adolescents, adult depression research, and practical experience.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H4\">",
"     <span class=\"h1\">",
"      COUNSELING TO TREAT DEPRESSION",
"     </span>",
"    </p>",
"    <p>",
"     Psychological treatments, also called psychotherapy, talk therapy, or counseling, teaches patients and their families to understand themselves and the nature of depression, including how to deal with low mood, engage in productive behaviors, manage relationships and develop effective problem solving strategies for life stressors associated with depression.",
"    </p>",
"    <p>",
"     Therapy sessions are usually conducted in the therapist's office once per week for 30 to 60 minutes. The adolescent, parents, and therapist should work together to determine the optimal schedule.",
"    </p>",
"    <p>",
"     During a therapy session, the teen talks to the therapist about their feelings, thoughts, behaviors, and relationships. The patient and therapist can discuss alternate ways of thinking or taking action, which often helps the teen to cope more effectively with depressive symptoms, improve social and problem solving skills, and increase self-confidence.",
"    </p>",
"    <p>",
"     While it is important to involve parents in some aspects of their adolescent's treatment (particularly regarding education and ensuring safety), parents usually do not sit in the room with the teen and therapist throughout all therapy discussions. The reason for this is that adolescents have a right to privacy and may be reluctant to openly discuss important topics when parents are present.",
"    </p>",
"    <p>",
"     The initial therapy sessions often focus on trying to identify the factors that are contributing to and maintaining depression. Initial therapy often includes changing unproductive behavior patterns that are common during episodes of depression. Although psychotherapy can lessen depression within several weeks, the greatest benefit of therapy may not be seen for eight to 10 weeks or longer.",
"    </p>",
"    <p>",
"     Psychotherapy can be provided by a range of healthcare professionals with appropriate training, including a psychiatrist, psychologist, clinical social worker, or clinical nurse specialist. When choosing a therapist, it is important to consider the therapist's training and experience with adolescents and evidence based practice, as well as the therapist's willingness to incorporate family members in the therapy.",
"    </p>",
"    <p>",
"     Below are some examples of useful questions to ask of the therapist:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       What type of training or experience do you have treating depression in adolescents?",
"      </li>",
"      <li>",
"       Are family members included in some aspects of the treatment? How?",
"      </li>",
"      <li>",
"       What is your experience in using cognitive behavioral therapy (CBT) or interpersonal psychotherapy for depression? These types of therapy have been shown to be effective in adolescents.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Teens with severe depression and those at risk for suicide are often hospitalized in a psychiatric facility for a short period of time. During the hospitalization, the teen usually has a group of clinicians (psychiatrist, psychologist, social workers, etc.) who comprise the treatment team. Depression treatment often includes medication management, individual, group",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     family therapy. Other activities may include physical exercise,",
"     <span class=\"nowrap\">",
"      art/music",
"     </span>",
"     therapy and school work.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H5\">",
"     <span class=\"h1\">",
"      ANTIDEPRESSANT MEDICATION",
"     </span>",
"    </p>",
"    <p>",
"     If an adolescent needs an antidepressant medication, he or she may be treated by their pediatrician or referred to a psychiatrist.",
"    </p>",
"    <p>",
"     A psychiatrist is a medical doctor with specialized training in the treatment of mental health issues. The psychiatrist should have training and experience in child and adolescent psychiatry or, if the person has adult-only training, he or she should have experience treating teenagers. In some cases, a psychiatrist provides counseling and prescribes medications if needed; in other cases, a therapist provides counseling and a psychiatrist prescribes medication.",
"    </p>",
"    <p>",
"     Treatment with an antidepressant medication helps to reestablish the normal balance of chemicals in the brain. Classes of antidepressants used to treat depression in adolescents include: selective serotonin reuptake inhibitors (SSRIs) or other atypical antidepressants and tricyclic antidepressants (TCAs).",
"    </p>",
"    <p>",
"     If a healthcare provider recommends an antidepressant medication for an adolescent's depression, the following issues should be discussed before treatment begins:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       The expected benefits and possible risks and side effects",
"      </li>",
"      <li>",
"       The instructions for the dose and timing",
"      </li>",
"      <li>",
"       The length of time to response",
"      </li>",
"      <li>",
"       Potential interactions with other prescription or non-prescription medications",
"      </li>",
"      <li>",
"       Alternatives to medication (eg, continued therapy)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     An information sheet for parents about antidepressants in adolescents is provided in table 1 (",
"     <a class=\"graphic graphic_table graphicRef68418 \" href=\"UTD.htm?24/62/25581\">",
"      table 1",
"     </a>",
"     ). The American Academy of Child and Adolescent Psychiatry, in partnership with the American Psychiatric Association, also has a medication guide for parents, available online at",
"     <a class=\"external\" href=\"file://www.parentsmedguide.org/pmg_depression.html\">",
"      www.parentsmedguide.org/pmg_depression.html",
"     </a>",
"     .",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Selective serotonin reuptake inhibitors (SSRIs)",
"     </span>",
"     &nbsp;&mdash;&nbsp;The selective serotonin reuptake inhibitors (SSRIs) increase levels of the neurochemical serotonin in the brain. Low levels of serotonin may be one cause of depression. SSRIs are generally the first-line medication for depression in adolescents because there are few or no side effects and the medication is only taken once per day.",
"    </p>",
"    <p>",
"     SSRIs that have been studied for use in adolescents include fluoxetine (Prozac&reg;), sertraline (Zoloft&reg;), paroxetine (Paxil&reg;), citalopram (Celexa&reg;), and escitalopram (Lexapro). There are two antidepressants approved by the United States Food and Drug Administration (FDA) to treat depression in youth. Fluoxetine is approved in youth eight years and older and escitalopram is approved in youth 12 years and older. However, there may be sound clinical reasons to prescribe an antidepressant other than fluoxetine or escitalopram. Questions or concerns about any antidepressant should be discussed with the individual clinician.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h3\">",
"      Side effects",
"     </span>",
"     &nbsp;&mdash;&nbsp;Side effects of SSRI antidepressants often improve with time (one to two weeks), but may include headache, abdominal pain, diarrhea and nausea, sleep changes, jitteriness, agitation, or sexual side effects (decreased libido, delayed ability or inability to experience",
"     <span class=\"nowrap\">",
"      orgasm/ejaculate).",
"     </span>",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Serotonin",
"       syndrome &mdash; A more serious potential side effect of SSRIs is serotonin syndrome. Symptoms of serotonin syndrome can include agitation, confusion, and overheating (hyperthermia). This can occur with high doses of an SSRI or if an SSRI is taken in combination with another antidepressant medication called a monoamine oxidase inhibitor (MAOI).",
"       <br/>",
"       <br/>",
"       There is a very small risk of serotonin syndrome when an SSRI is combined with a class of migraine medications called triptans (eg, sumatriptan (Imitrex&reg;), zolmitriptan (Zomig&reg;), naratriptan (Amerge&reg;), rizatriptan (Maxalt&reg;), almotriptan (Axert&reg;), eletriptan (Relpax&reg;) and frovatriptan (Frova&reg;)). Many headache experts feel that it is safe to use an SSRI and a triptan in combination as long as the person is monitored for symptoms.",
"       <br/>",
"      </li>",
"      <li>",
"       Risk of suicide &mdash; Depression significantly increases an adolescent's risk of having suicidal thoughts and committing suicide. Many parents are concerned about a possible association between suicide and antidepressant medications.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     It is not clear if antidepressants increase the risk of a teenager actually committing suicide. However antidepressants have been associated with a slightly increased risk of suicidal thinking in adolescents and young adults, particularly during the initial weeks of treatment.",
"    </p>",
"    <p>",
"     In considering whether or not to use medication to treat depression, the parent(s) and psychiatrist must balance the small increased risk of suicidal thoughts against the very real risk of suicide if the teen's depression is not adequately treated. Any mention of suicidal thoughts or feelings in a depressed adolescent should be taken seriously.",
"    </p>",
"    <p>",
"     Parents who are concerned that their child is considering suicide should seek care as soon as possible. A depressed adolescent who is at risk of attempting suicide will be provided with emergency treatment for depression; this may include hospitalization, antidepressant medication, and intensive therapy.",
"    </p>",
"    <p>",
"     Treatment of depression decreases the risk of suicide, but does not eliminate the risk. For this reason, most experts recommend that the parents and healthcare providers (eg, therapist, psychiatrist, pediatrician) closely monitor the adolescent for evidence of suicidal thoughts or behaviors for at least the first 12 weeks of depression treatment and if the antidepressant medication dose is changed.",
"    </p>",
"    <p>",
"     If suicidal thoughts or behaviors develop during treatment with an antidepressant, the dose may be adjusted, an alternative antidepressant may be tried, or the medication may be discontinued.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      Atypical antidepressants",
"     </span>",
"     &nbsp;&mdash;&nbsp;Atypical antidepressants may be considered if the first line treatment is not effective or cannot be tolerated. Available options include venlafaxine (Effexor&reg;), desvenlafaxine (Pristiq&reg;), duloxetine (Cymbalta&reg;), mirtazapine (Remeron&reg;), and bupropion (Wellbutrin&reg;). However, these medications are not well studied in children and adolescents.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      Tricyclic antidepressants",
"     </span>",
"     &nbsp;&mdash;&nbsp;Tricyclic antidepressants (TCAs) alter levels of several different neurochemicals in the brain. Drugs in this class include imipramine (Tofranil&reg;), amitriptyline (Elavil&reg;), desipramine (Norpramin&reg;), nortriptyline (Pamelor&reg;), and clomipramine (Anafranil&reg;).",
"    </p>",
"    <p>",
"     Because of the numerous side effects associated with these drugs and the availability of an effective alternative (SSRIs), TCAs are less commonly used as a first-line treatment. The side effects of TCAs may include dry mouth, blurred vision, constipation, nausea, difficulty urinating, drowsiness, weight gain, and rapid heartbeat.",
"    </p>",
"    <p>",
"     Nevertheless, many patients use TCAs safely, and their benefit is equivalent to that of other antidepressants.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H10\">",
"     <span class=\"h1\">",
"      ANTIDEPRESSANT MEDICATION ISSUES",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      Time required for a response",
"     </span>",
"     &nbsp;&mdash;&nbsp;Some people respond to antidepressant medication after about two weeks, but for most, the full effect is not seen until four to six weeks or longer. During the first few weeks, the dose is usually increased gradually. The adolescent usually sees the medical provider (the psychiatrist) once per week for the first four weeks, then every two weeks for the next four weeks, and then every one to three months; if problems develop at any point, more frequent visits may be recommended. This usually means that the teen will have at least two appointments per week for medication monitoring and counseling during the first few months of treatment.",
"    </p>",
"    <p>",
"     By six to eight weeks after starting an antidepressant medication, it is usually possible to determine if the medication is effective. If symptoms have improved somewhat during this time, the dose of the medication may be increased. If there has been no improvement in symptoms, an alternate antidepressant medication may be recommended.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      Duration",
"     </span>",
"     &nbsp;&mdash;&nbsp;In most cases, the antidepressant medication is continued for at least nine to 12 months after the symptoms of depression improve. This recommendation varies greatly depending upon the individual's situation. The decision to stop antidepressant medication should be shared between the adolescent, parent(s), and the clinician.",
"    </p>",
"    <p>",
"     When antidepressants are stopped, they should be tapered slowly over two to four weeks to minimize the potential side effects associated with abruptly stopping medication. Side effects associated with stopping antidepressant medication quickly can include jitteriness, dizziness, nausea, fatigue, muscle aches, chills, anxiety, and irritability. Although these symptoms are not dangerous and usually improve over one to two weeks, they can be quite distressing and uncomfortable.",
"    </p>",
"    <p>",
"     A relapse in depression is relatively common after stopping antidepressant medications; in some cases, longer-term treatment is recommended (see",
"     <a class=\"local\" href=\"#H13\">",
"      'Maintenance drug therapy'",
"     </a>",
"     below)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h2\">",
"      Maintenance drug therapy",
"     </span>",
"     &nbsp;&mdash;&nbsp;Maintenance drug therapy (long-term antidepressant therapy) may be appropriate for adolescents who are at high risk for a relapse of depression. One study found that 37 percent of adults who were treated for depression experienced a relapse within 12 months of stopping antidepressant therapy [",
"     <a class=\"abstract\" href=\"UTD.htm?28/21/29013/abstract/4\">",
"      4",
"     </a>",
"     ]. Maintenance therapy may last from one year to indefinitely, depending upon the individual's situation and personal history of depression.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h2\">",
"      Therapy with other medications",
"     </span>",
"     &nbsp;&mdash;&nbsp;In some people, depression is accompanied by other psychiatric conditions, such as panic attacks, obsessive-compulsive disorder, or mania. Treatment with more than one medication, including an antidepressant and an antipsychotic, antianxiety, mood-stabilizing, or anticonvulsant medication may be recommended in this situation.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H15\">",
"     <span class=\"h1\">",
"      OTHER TREATMENT OPTIONS FOR DEPRESSION",
"     </span>",
"    </p>",
"    <p>",
"     Several other treatment options may alleviate depression in some people.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h2\">",
"      Omega-3 fatty acids",
"     </span>",
"     &nbsp;&mdash;&nbsp;A large international study found a beneficial effect of omega-3 fatty acids, which are found in fish, in the treatment of depression in adults [",
"     <a class=\"abstract\" href=\"UTD.htm?28/21/29013/abstract/5\">",
"      5",
"     </a>",
"     ]. A small trial also found a benefit in children, although further studies are needed to confirm these results [",
"     <a class=\"abstract\" href=\"UTD.htm?28/21/29013/abstract/6\">",
"      6",
"     </a>",
"     ].",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17\">",
"     <span class=\"h2\">",
"      St. John's wort",
"     </span>",
"     &nbsp;&mdash;&nbsp;St. John's wort (Hypericum perforatum) appears to alter levels of several neurochemicals in the brain. Studies in adults suggest that St. John's wort is more effective than a placebo and as effective as tricyclic antidepressants for the treatment of mild to moderate depression [",
"     <a class=\"abstract\" href=\"UTD.htm?28/21/29013/abstract/7\">",
"      7",
"     </a>",
"     ]. However, antidepressant medications are not usually recommended for adolescents with mild to moderate depression, and St. John's wort has not been studied adequately in adolescents.",
"    </p>",
"    <p>",
"     A good source for updated information about St. John's wort can be found at the National Center for Complementary and Alternative Medicine, a branch of the National Institutes of Health (",
"     <a class=\"external\" href=\"file://www.nccam.nih.gov/health/stjohnswort/\">",
"      www.nccam.nih.gov/health/stjohnswort/",
"     </a>",
"     ).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18\">",
"     <span class=\"h2\">",
"      Electroconvulsive therapy (ECT)",
"     </span>",
"     &nbsp;&mdash;&nbsp;During electroconvulsive therapy (ECT), an electrical current is passed through the brain, triggering a seizure. For unknown reasons, the seizure helps to restore the normal balance of neurochemicals in the brain. ECT is especially effective for people with depression who also have delusions (powerful, irrational beliefs) and for people who have severe depression that has not improved with maximal drug therapy. The parent(s), adolescent, and psychiatrist must all agree to a trial of ECT before it is considered; state and local guidelines may also apply. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/41/21145?source=see_link\">",
"      \"Medical consultation for electroconvulsive therapy\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Patients who undergo ECT are given general anesthesia to induce sleep and prevent discomfort. The patient is monitored carefully before, during, and after the treatment. Side effects of this therapy include brief confusion and memory loss. Although ECT has been negatively portrayed in the media, it often provides rapid and dramatic relief of depression and has few side effects. Most people who undergo ECT find it a helpful treatment for their depression.",
"    </p>",
"    <p>",
"     More detailed information about ECT is available on the American Psychiatric Association's web site,",
"     <a class=\"external\" href=\"file://www.psych.org/Departments/APIREandResearch/ResearchTraining/clin_res/index.aspx\">",
"      www.psych.org/Departments/APIREandResearch/ResearchTraining/clin_res/index.aspx",
"     </a>",
"     .",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H19\">",
"     <span class=\"h1\">",
"      ANTIDEPRESSANTS AND PREGNANCY",
"     </span>",
"    </p>",
"    <p>",
"     Information about the safety of antidepressant medications in pregnancy is available in a separate topic review. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/24/21894?source=see_link&amp;anchor=H25#H25\">",
"      \"Patient information: Depression treatment options for adults (Beyond the Basics)\", section on 'Antidepressants and pregnancy'",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H20\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your adolescent&rsquo;s healthcare provider is the best source of information for questions and concerns related to your adolescent&rsquo;s medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H201\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6664152\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/57/12179?source=see_link\">",
"      Patient information: Depression (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/6/24675?source=see_link\">",
"      Patient information: Medicines for depression (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?36/15/37106?source=see_link\">",
"      Patient information: Electroconvulsive therapy (ECT) (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?8/45/8914?source=see_link\">",
"      Patient information: Post-traumatic stress disorder (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/18/11554?source=see_link\">",
"      Patient information: When you have depression and another health problem (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6664208\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?13/6/13413?source=see_link\">",
"      Patient information: Depression in adolescents (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?19/41/20116?source=see_link\">",
"      Patient information: Depression in adults (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/24/21894?source=see_link\">",
"      Patient information: Depression treatment options for adults (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H22\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/29/40410?source=see_link\">",
"      Complications and screening in children and adolescents with type 1 diabetes mellitus",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/10/5289?source=see_link\">",
"      Depression in adolescents: Epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/23/15736?source=see_link\">",
"      Effect of antidepressants on suicide risk in children and adolescents",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/17/23834?source=see_link\">",
"      Suicidal behavior in children and adolescents: Epidemiology and risk factors",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/11/38071?source=see_link\">",
"      Evaluation and management of suicidal behavior in children and adolescents",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/26/13738?source=see_link\">",
"      Overview of treatment for adolescent depression",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/52/30538?source=see_link\">",
"      Psychopharmacological treatment for adolescent depression",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/14/4328?source=see_link\">",
"      Psychosocial treatment for adolescent depression",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/41/21145?source=see_link\">",
"      Medical consultation for electroconvulsive therapy",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"      www.nlm.nih.gov/medlineplus/healthtopics.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The American Academy of Child and Adolescent Psychiatry (AACAP)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.aacap.org/\">",
"      www.aacap.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Federal Drug Administration",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/UCM096273\">",
"      www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/UCM096273",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The American Psychiatric Association",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.psych.org/\">",
"      www.psych.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Psychological Association",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.apa.org/\">",
"      www.apa.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Anxiety and Depression Association of America (ADAA)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.adaa.org/\">",
"      www.adaa.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Association for Behavioral and Cognitive Therapies (ABCT)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(www.abct.org)",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Alliance for the Mentally Ill",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nami.org/\">",
"      www.nami.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Institute of Mental Health",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nimh.nih.gov/health/topics/depression/index.shtml\">",
"      www.nimh.nih.gov/health/topics/depression/index.shtml",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Mental Health Association",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nmha.org/\">",
"      www.nmha.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?28/21/29013/abstract/4-10\">",
"      4-10",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 31, 2013.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?28/21/29013?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29013/abstract/1\">",
"      March J, Silva S, Petrycki S, et al. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial. JAMA 2004; 292:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29013/abstract/2\">",
"      Birmaher B, Brent DA, Kolko D, et al. Clinical outcome after short-term psychotherapy for adolescents with major depressive disorder. Arch Gen Psychiatry 2000; 57:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29013/abstract/3\">",
"      Brent D, Emslie G, Clarke G, et al. Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial. JAMA 2008; 299:901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29013/abstract/4\">",
"      Keller MB, Kocsis JH, Thase ME, et al. Maintenance phase efficacy of sertraline for chronic depression: a randomized controlled trial. JAMA 1998; 280:1665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29013/abstract/5\">",
"      Parker G, Gibson NA, Brotchie H, et al. Omega-3 fatty acids and mood disorders. Am J Psychiatry 2006; 163:969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29013/abstract/6\">",
"      Nemets H, Nemets B, Apter A, et al. Omega-3 treatment of childhood depression: a controlled, double-blind pilot study. Am J Psychiatry 2006; 163:1098.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29013/abstract/7\">",
"      Goodyer I, Dubicka B, Wilkinson P, et al. Selective serotonin reuptake inhibitors (SSRIs) and routine specialist care with and without cognitive behaviour therapy in adolescents with major depression: randomised controlled trial. BMJ 2007; 335:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29013/abstract/8\">",
"      Hazell P, O'Connell D, Heathcote D, Henry D. Tricyclic drugs for depression in children and adolescents. Cochrane Database Syst Rev 2002; :CD002317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29013/abstract/9\">",
"      Ma J, Lee KV, Stafford RS. Depression treatment during outpatient visits by U.S. children and adolescents. J Adolesc Health 2005; 37:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29013/abstract/10\">",
"      Leslie LK, Newman TB, Chesney PJ, Perrin JM. The Food and Drug Administration's deliberations on antidepressant use in pediatric patients. Pediatrics 2005; 116:195.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f28_21_29013=[""].join("\n");
var outline_f28_21_29013=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           DEPRESSION OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           STEP ONE: EDUCATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           DEPRESSION TREATMENT OPTIONS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H4\">",
"           COUNSELING TO TREAT DEPRESSION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H5\">",
"           ANTIDEPRESSANT MEDICATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H10\">",
"           ANTIDEPRESSANT MEDICATION ISSUES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H15\">",
"           OTHER TREATMENT OPTIONS FOR DEPRESSION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H19\">",
"           ANTIDEPRESSANTS AND PREGNANCY",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H20\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          TABLES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_table\" href=\"UTD.htm?24/62/25581\" title=\"table 1\">",
"           Antidepressants PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f28_21_29014="Surgical management of congenital uterine anomalies";
var content_f28_21_29014=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Surgical management of congenital uterine anomalies",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/21/29014/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/21/29014/contributors\">",
"     Ronald E Iverson, Jr, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/21/29014/contributors\">",
"     Alan H DeCherney, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/21/29014/contributors\">",
"     Marc R Laufer, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/21/29014/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/21/29014/contributors\">",
"     Robert L Barbieri, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/21/29014/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/21/29014/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/21/29014/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 25, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Congenital uterine anomalies are associated with a variety of gynecological and obstetrical problems. &nbsp;Restoration of normal uterine architecture and preservation of fertility are the goals of surgical treatment of uterine anomalies (",
"    <a class=\"graphic graphic_table graphicRef76124 \" href=\"UTD.htm?2/32/2572\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef81036 \" href=\"UTD.htm?33/40/34439\">",
"     figure 1",
"    </a>",
"    ). However, normal or near-normal architecture cannot always be achieved and merely creating a normal uterine cavity may not be therapeutic because uterine vascularization and myometrial and cervical function may also be abnormal.",
"   </p>",
"   <p>",
"    Surgical management of congenital uterine anomalies is reviewed here. The evaluation and diagnosis of women with congenital uterine anomalies is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/0/26633?source=see_link\">",
"     \"Clinical manifestations and diagnosis of congenital anomalies of the uterus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical repair of congenital uterine anomalies is primarily directed toward women with uterine septa, bicornuate uteri, and obstructed hemi-uteri. Women with unicornuate or arcuate uteri are generally not candidates for reconstructive procedures because surgery does not improve pregnancy outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29014/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most common indications for repair of congenital uterine anomalies are pelvic pain and repetitive pregnancy loss. Prior to surgical intervention, however, other causes of these problems should be excluded. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/3/26679?source=see_link\">",
"     \"Evaluation of couples with recurrent pregnancy loss\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Dysmenorrhea in women with septate uteri may be considered an indication for hysteroscopic metroplasty if medical therapy is not effective. Laparoscopic evaluation for coexistent endometriosis (common in women with structural abnormalities of the reproductive tract) should be undertaken.",
"   </p>",
"   <p>",
"    We, and others [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29014/abstract/2,3\">",
"     2,3",
"    </a>",
"    ], do not believe abdominal repair of the didelphic uterus to improve pregnancy outcome is sufficiently supported by existing data. Pregnancy outcomes in women with bicornuate uteri have been reported to be close to those of the general population. However, since some of these women have recurrent pregnancy loss, surgical treatment with uterine reunification via laparoscopy or laparotomy may be indicated after other possible causes of recurrent pregnancy loss have been addressed.",
"   </p>",
"   <p>",
"    Surgical correction is not warranted in asymptomatic women or those with primary infertility. Uterine abnormalities typically don't prevent conception and implantation. As an example, one series of 228 women with uterine anomalies noted that 9.1 percent had primary infertility, and most of these cases could be explained by other defects [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29014/abstract/4\">",
"     4",
"    </a>",
"    ]. Most authorities agree that primary infertility in the presence of uterine anomalies is",
"    <strong>",
"     not",
"    </strong>",
"    an indication for metroplasty. However, metroplasty may be considered after a complete diagnostic evaluation has been performed and appropriate therapeutic interventions have failed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     OBSTRUCTED UTERINE RUDIMENTARY HORNS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with m&uuml;llerian aplasia or a unicornuate uterus and cyclic or chronic abdominal or pelvic pain may have a noncommunicating uterine horn with functional endometrium (",
"    <a class=\"graphic graphic_figure graphicRef69536 graphicRef61993 \" href=\"UTD.htm?5/53/5970\">",
"     figure 2A-B",
"    </a>",
"    ). MRI or ultrasound are useful in identifying the noncommunicating uterine horn and determining whether an endometrial stripe is present.",
"   </p>",
"   <p>",
"    Patients with an obstructed uterine horn are at increased risk of endometriosis, but the endometriosis usually resolves after the removal of the obstructed hemiuterus. Excision of the obstructed rudimentary blind horn will prevent endometriosis by eliminating reflux, and will also prevent development of a pregnancy (and pregnancy complications) in the obstructed uterine horn (",
"    <a class=\"graphic graphic_picture graphicRef67507 graphicRef81269 \" href=\"UTD.htm?40/59/41911\">",
"     picture 1A-B",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29014/abstract/5\">",
"     5",
"    </a>",
"    ]. The obstructed rudimentary noncommunicating uterine horn should be removed laparoscopically [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29014/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     HYSTEROSCOPIC REPAIR OF THE SEPTATE UTERUS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hysteroscopic metroplasty has become the method of choice for repair of most uterine septa. Benefits to the transcervical approach include less morbidity, no abdominal or transmyometrial incisions, and faster return to normal activity. As there is no abdominal incision, possible infections and intra-abdominal adhesions that may cause future infertility problems or pain are avoided. Women may attempt pregnancy sooner after a",
"    <span class=\"nowrap\">",
"     vaginal/transcervical",
"    </span>",
"    approach than after abdominal procedures. Vaginal delivery is not contraindicated.",
"   </p>",
"   <p>",
"    Various techniques and instruments are used either to incise or remove the septum, including semirigid or rigid scissors (7 French) or unipolar wire loop (8 mm) urologic resectoscope (21 to 26 French sheath); Versapoint&reg; bipolar electrode (1.6 mm; 5 mm sheath); or Potassium-titan-phosphate",
"    <span class=\"nowrap\">",
"     (KTP/532),",
"    </span>",
"    neodynamic:yttrium aluminum garnet (Nd:YAG), or argon lasers.",
"   </p>",
"   <p>",
"    Use of any of the above instruments is associated with good success rates and infrequent complications. Use of microscissors or bipolar electrode may decrease operating time [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29014/abstract/7-9\">",
"     7-9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Procedure",
"    </span>",
"    &nbsp;&mdash;&nbsp;The procedure can be done with laparoscopic assistance, both to evaluate the external uterus and to observe the myometrium in an attempt to decrease the risk of perforation. Some operators use progestational agents preoperatively to further atrophy the lining, but this is not necessary.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/0/26629?source=see_link\">",
"     Danazol",
"    </a>",
"    is slightly better than gonadotropin releasing hormone agonists because of lower cost and side effects [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29014/abstract/10\">",
"     10",
"    </a>",
"    ]. After evaluation of the pelvic organs with the laparoscope, the uterus is instilled with glycine,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/5/21588?source=see_link\">",
"     dextran",
"    </a>",
"    or another appropriate medium. If two cervices are noted, a Foley balloon may be inserted into one os to prevent leakage of the distension media (",
"    <a class=\"graphic graphic_figure graphicRef64519 \" href=\"UTD.htm?38/30/39400\">",
"     figure 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    A partial septum may require only incision of the septum. Alternatively, with a partial or a complete septum, the septal tissue can be removed. In deciding which technique to use, the surgeon should remember that the goal is to reduce the septal surface area.",
"   </p>",
"   <p>",
"    The broad flat fundus of the septate uterus can be seen in the picture (",
"    <a class=\"graphic graphic_picture graphicRef65245 \" href=\"UTD.htm?34/22/35172\">",
"     picture 2",
"    </a>",
"    ). Surgical resection of a septum using a wire is demonstrated in the following pictures (",
"    <a class=\"graphic graphic_picture graphicRef79425 graphicRef53717 graphicRef62456 \" href=\"UTD.htm?18/6/18538\">",
"     picture 3A-C",
"    </a>",
"    ). With the resection technique, the wire is place in one endometrial cavity and moved horizontally to the other side, thereby removing the septal tissue.",
"   </p>",
"   <p>",
"    It can be difficult to recognize when the base of the septum has been reached. One approach is to continue cutting until increased bleeding is noted, since the septum often has poor blood supply compared to the myometrium, but this approach will not work if a coagulative instrument is used. Alternatively, if laparoscopy is performed at the same time, the laparoscope can be used to visualize when the hysteroscopic resection is getting too close to the uterine serosal surface, especially if the laparoscopic light is dimmed so that the hysteroscopic light can be appreciated.",
"   </p>",
"   <p>",
"    On completion of the procedure, the surgeon should be able to visualize the fundus and sweep easily between ostia. The uterine cavity should appear normal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Postoperative care",
"    </span>",
"    &nbsp;&mdash;&nbsp;No further treatment is required postoperatively. Intrauterine devices, Foley balloons, high-dose estrogen, and antibiotics are not necessary [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29014/abstract/11\">",
"     11",
"    </a>",
"    ]. Formation of intrauterine synechiae is rare, as are postoperative infections. Endogenous estrogen is sufficient to promote new endometrium within two months of hysteroscopic metroplasty [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29014/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An HSG should be performed two months after surgery to assess success. Typically, over 90 percent of the septum is removed during the procedure. Occasionally, further repairs of the septum are required, again in an ambulatory setting [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29014/abstract/11,13\">",
"     11,13",
"    </a>",
"    ]. In one series, a residual fundal notch greater than 1 cm on follow-up hysteroscopy was considered an indication for repeating the septoplasty [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29014/abstract/13\">",
"     13",
"    </a>",
"    ]. Attempts at pregnancy may begin two months postoperatively if the procedure is deemed adequate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6324043\">",
"    <span class=\"h2\">",
"     Outcome",
"    </span>",
"    &nbsp;&mdash;&nbsp;A meta-analysis of 29 observational studies that evaluated hysteroscopic metroplasty in women who were not treated with in vitro fertilization found a pregnancy rate of 64 percent and a live birth rate of 54 percent after the procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29014/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     LAPAROSCOPIC/ABDOMINAL TRANSMYOMETRIAL REPAIR OF THE SEPTATE UTERUS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most uterine septums can be successfully surgically addressed hysteroscopically. If however the septum cannot be safely removed hysteroscopically, then an abdominal or laparoscopic approach, such as the Jones or Tompkins metroplasty, can be used.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Jones metroplasty",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Jones procedure refers to a wedge resection of the portion of the uterine fundus containing the septum (",
"    <a class=\"graphic graphic_figure graphicRef71446 graphicRef50489 graphicRef66362 \" href=\"UTD.htm?42/47/43770\">",
"     figure 4A-C",
"    </a>",
"    ). The operator draws a triangular incision line forming a wedge in the anterior-posterior plane of the uterus. Vasopressin can be injected into the myometrium (10 units in 30 mL of saline) to reduce bleeding when the uterus is subsequently incised. Alternatively, a tourniquet, such as a 0.5 Penrose drain, may be placed through an avascular space in the broad ligament just lateral to the uterine vessels and tied at the junction of the lower uterine segment and the cervix. Using the same holes in the broad ligament, tourniquets should also be secured on the infundibulopelvic ligaments bilaterally. It is important that arterial flow is stopped, since uterine congestion and bleeding are increased if only the venous flow is restricted. Sutures should be placed bilaterally for traction, lateral to the area of planned resection. The wedge is then incised until the common uterine cavity is found and the septum can be totally removed.",
"   </p>",
"   <p>",
"    Reconstruction of the uterus begins at the lower portion of the cavity. The anterior and then posterior walls are closed in either a continuous or interrupted fashion. Some operators inject",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/7/1143?source=see_link\">",
"     methylene blue",
"    </a>",
"    into the uterine cavity prior to the incision, so that the endometrium is easily identified. The first layer should include the endometrium and a small amount of myometrium. The knot should be tied so that it remains in the uterine cavity. The second closure layer is begun inferiorly and performed with interrupted sutures that include the remainder of the myometrium. The final layer, using light suture in a continuous or interrupted fashion, contains the remainder of the myometrium and serosa, attempting to imbricate the rough serosal edges.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Tompkins metroplasty",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Tompkins metroplasty is similar to the Jones procedure, except that no tissue is removed (",
"    <a class=\"graphic graphic_figure graphicRef67827 graphicRef79101 graphicRef58593 \" href=\"UTD.htm?43/27/44474\">",
"     figure 5A-C",
"    </a>",
"    ). The uterus is incised in the midline anterior-posterior plane until the uterine cavity is reached. The bilateral cavities are then unroofed, using sharp dissection, and the uterus is closed as in the Jones procedure. The benefit of this technique is that the resultant uterine cavity is larger than with wedge resection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     OUTCOME",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Fetal salvage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Improved fetal survival has been demonstrated for all of the above described procedures. The successful pregnancy rate after hysteroscopic metroplasty is 85 to 90 percent, which compares favorably with preoperative fetal salvage rates of 5 to 10 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29014/abstract/15-20\">",
"     15-20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several series on abdominal metroplasty reported improvement in fetal survival from 3 to 12 percent preoperatively to 65 to 90 percent postoperatively [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29014/abstract/21-26\">",
"     21-26",
"    </a>",
"    ]. However, others have questioned whether metroplasty truly improves outcome for women with repetitive abortions. In a study of 146 women with bicornuate, septate, or didelphic uterus, 30 of whom were matched, no increase in the number of living children was found after metroplasty in the matched group [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29014/abstract/27\">",
"     27",
"    </a>",
"    ]. Consecutive pregnancies in an abnormal uterus may carry longer so that eventually some women will deliver nearer to term without surgery. In addition, women with septate uteri may also have subfertility due to other abnormalities, which may not be corrected by surgery. As an example, a review of women with primary infertility and septate uterus reported the mean pregnancy rate after hysteroscopic metroplasty was only 48 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29014/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Reduction in pregnancy complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The frequency of malpresentation, retained placenta, and intrauterine growth restriction associated with m&uuml;llerian abnormalities should return to that of the general population after repair. It is unclear whether there is an improvement in preterm birth rate [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29014/abstract/29\">",
"     29",
"    </a>",
"    ]. Minimal data are available [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29014/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Reduction in dysmenorrhea",
"    </span>",
"    &nbsp;&mdash;&nbsp;A prospective study of dysmenorrhea reported by women who underwent Tompkins (n = 28) or hysteroscopic (n = 62) metroplasty for septate uteri found that the frequency of dysmenorrhea fell from 50 to 32 percent after the Tompkins procedure and from 55 to 18 percent after hysteroscopic treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29014/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is an increased risk of uterine rupture with procedures requiring fundal hysterotomy. Most authors recommend cesarean delivery for these women. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/10/5290?source=see_link\">",
"     \"Choosing the route of delivery after cesarean birth\"",
"    </a>",
"    .) Uterine rupture has also been reported rarely after hysteroscopic procedures, but attempted vaginal delivery is generally recommended after these procedures in the absence of other obstetrical indications for cesarean birth [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29014/abstract/32-34\">",
"     32-34",
"    </a>",
"    ]. In complex uterine anomaly cases, an option of adoption or gestational carrier should be addressed with the patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Surgical correction of a congenital uterine anomaly is not warranted in asymptomatic women or those with primary infertility. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Obstructed hemi-uteri or uterine horns should be resected laparoscopically. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Obstructed uterine rudimentary horns'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We, and others, do not believe abdominal repair of the didelphic uterus to improve pregnancy outcome is sufficiently supported by existing data. Pregnancy outcomes in women with bicornuate uteri have been reported to be close to those of the general population. However, since some of these women have recurrent pregnancy loss, surgical treatment with uterine reunification via laparotomy may be indicated after other possible causes of recurrent pregnancy loss have been addressed. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hysteroscopic repair is the procedure of choice for women with recurrent miscarriage and a septate uterus. An HSG should be performed two months after surgery to assess success. Typically, over 90 percent of the septum is removed during the procedure. Further repairs of the septum are indicated if more than 1 cm of septum remains. Attempts at pregnancy may begin two months postoperatively if the procedure is deemed adequate. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Hysteroscopic repair of the septate uterus'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If the septum cannot be safely removed hysteroscopically, then an abdominal approach, such as the Jones or Tompkins metroplasty, can be used. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Laparoscopic/abdominal transmyometrial repair of the septate uterus'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29014/abstract/1\">",
"      Aci&eacute;n P, Aci&eacute;n M, S&aacute;nchez-Ferrer M. Complex malformations of the female genital tract. New types and revision of classification. Hum Reprod 2004; 19:2377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29014/abstract/2\">",
"      Musich JR, Behrman SJ. Obstetric outcome before and after metroplasty in women with uterine anomalies. Obstet Gynecol 1978; 52:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29014/abstract/3\">",
"      Lin PC, Bhatnagar KP, Nettleton GS, Nakajima ST. Female genital anomalies affecting reproduction. Fertil Steril 2002; 78:899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29014/abstract/4\">",
"      Heinonen PK, Pystynen PP. Primary infertility and uterine anomalies. Fertil Steril 1983; 40:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29014/abstract/5\">",
"      Kirschner R, L&ouml;fstrand T, Mark J. Pregnancy in a non-communicating, rudimentary uterine horn. A reason for failed therapeutic second trimester abortion. Acta Obstet Gynecol Scand 1979; 58:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29014/abstract/6\">",
"      Laufer, MR. Laparoscopic resection of obstructed hemi-uteri in a series of adolescents. J Pediatr Adolesc Gynecol 1997; 10:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29014/abstract/7\">",
"      Candiani GB, Vercellini P, Fedele L, et al. Argon laser versus microscissors for hysteroscopic incision of uterine septa. Am J Obstet Gynecol 1991; 164:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29014/abstract/8\">",
"      Vercellini P, Vendola N, Colombo A, et al. Hysteroscopic metroplasty with resectoscope or microscissors for the correction of septate uterus. Surg Gynecol Obstet 1993; 176:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29014/abstract/9\">",
"      Colacurci N, De Franciscis P, Mollo A, et al. Small-diameter hysteroscopy with Versapoint versus resectoscopy with a unipolar knife for the treatment of septate uterus: a prospective randomized study. J Minim Invasive Gynecol 2007; 14:622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29014/abstract/10\">",
"      Fedele L, Bianchi S, Gruft L, et al. Danazol versus a gonadotropin-releasing hormone agonist as preoperative preparation for hysteroscopic metroplasty. Fertil Steril 1996; 65:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29014/abstract/11\">",
"      Vercellini P, Fedele L, Arcaini L, et al. Value of intrauterine device insertion and estrogen administration after hysteroscopic metroplasty. J Reprod Med 1989; 34:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29014/abstract/12\">",
"      Candiani GB, Vercellini P, Fedele L, et al. Repair of the uterine cavity after hysteroscopic septal incision. Fertil Steril 1990; 54:991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29014/abstract/13\">",
"      Fedele L, Arcaini L, Parazzini F, et al. Reproductive prognosis after hysteroscopic metroplasty in 102 women: life-table analysis. Fertil Steril 1993; 59:768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29014/abstract/14\">",
"      Valle RF, Ekpo GE. Hysteroscopic metroplasty for the septate uterus: review and meta-analysis. J Minim Invasive Gynecol 2013; 20:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29014/abstract/15\">",
"      March CM, Israel R. Hysteroscopic management of recurrent abortion caused by septate uterus. Am J Obstet Gynecol 1987; 156:834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29014/abstract/16\">",
"      Valle RF, Sciarra JJ. Hysteroscopic treatment of the septate uterus. Obstet Gynecol 1986; 67:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29014/abstract/17\">",
"      Fayez JA. Comparison between abdominal and hysteroscopic metroplasty. Obstet Gynecol 1986; 68:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29014/abstract/18\">",
"      Choe JK, Baggish MS. Hysteroscopic treatment of septate uterus with Neodymium-YAG laser. Fertil Steril 1992; 57:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29014/abstract/19\">",
"      Heinonen PK, Saarikoski S, Pystynen P. Reproductive performance of women with uterine anomalies. An evaluation of 182 cases. Acta Obstet Gynecol Scand 1982; 61:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29014/abstract/20\">",
"      Patton PE, Novy MJ, Lee DM, Hickok LR. The diagnosis and reproductive outcome after surgical treatment of the complete septate uterus, duplicated cervix and vaginal septum. Am J Obstet Gynecol 2004; 190:1669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29014/abstract/21\">",
"      Rock JA, Jones HW Jr. The clinical management of the double uterus. Fertil Steril 1977; 28:798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29014/abstract/22\">",
"      Khalifa E, Toner JP, Jones HW Jr. The role of abdominal metroplasty in the era of operative hysteroscopy. Surg Gynecol Obstet 1993; 176:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29014/abstract/23\">",
"      Candiani GB, Fedele L, Parazzini F, Zamberletti D. Reproductive prognosis after abdominal metroplasty in bicornuate or septate uterus: a life table analysis. Br J Obstet Gynaecol 1990; 97:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29014/abstract/24\">",
"      Ayhan A, Y&uuml;cel I, Tuncer ZS, Ki��ni��&ccedil;i HA. Reproductive performance after conventional metroplasty: an evaluation of 102 cases. Fertil Steril 1992; 57:1194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29014/abstract/25\">",
"      Capraro VJ, Chuang JT, Randall CL. Improved fetal salvage after metroplasty. Obstet Gynecol 1968; 31:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29014/abstract/26\">",
"      Papp Z, Mezei G, G&aacute;vai M, et al. Reproductive performance after transabdominal metroplasty: a review of 157 consecutive cases. J Reprod Med 2006; 51:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29014/abstract/27\">",
"      Kirk EP, Chuong CJ, Coulam CB, Williams TJ. Pregnancy after metroplasty for uterine anomalies. Fertil Steril 1993; 59:1164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29014/abstract/28\">",
"      Pabu&ccedil;cu R, Gomel V. Reproductive outcome after hysteroscopic metroplasty in women with septate uterus and otherwise unexplained infertility. Fertil Steril 2004; 81:1675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29014/abstract/29\">",
"      Daly DC, Maier D, Soto-Albors C. Hysteroscopic metroplasty: six years' experience. Obstet Gynecol 1989; 73:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29014/abstract/30\">",
"      Heinonen PK. Reproductive performance of women with uterine anomalies after abdominal or hysteroscopic metroplasty or no surgical treatment. J Am Assoc Gynecol Laparosc 1997; 4:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29014/abstract/31\">",
"      Fedele L, Bianchi S, Bocciolone L, et al. Relief of dysmenorrhea associated with septate uteri after abdominal or hysteroscopic metroplasty. Acta Obstet Gynecol Scand 1994; 73:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29014/abstract/32\">",
"      Halvorson LM, Aserkoff RD, Oskowitz SP. Spontaneous uterine rupture after hysteroscopic metroplasty with uterine perforation. A case report. J Reprod Med 1993; 38:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29014/abstract/33\">",
"      Lobaugh ML, Bammel BM, Duke D, Webster BW. Uterine rupture during pregnancy in a patient with a history of hysteroscopic metroplasty. Obstet Gynecol 1994; 83:838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29014/abstract/34\">",
"      Angell NF, Tan Domingo J, Siddiqi N. Uterine rupture at term after uncomplicated hysteroscopic metroplasty. Obstet Gynecol 2002; 100:1098.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3292 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.243-684EC2BD62-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_21_29014=[""].join("\n");
var outline_f28_21_29014=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      OBSTRUCTED UTERINE RUDIMENTARY HORNS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      HYSTEROSCOPIC REPAIR OF THE SEPTATE UTERUS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Procedure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Postoperative care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6324043\">",
"      Outcome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      LAPAROSCOPIC/ABDOMINAL TRANSMYOMETRIAL REPAIR OF THE SEPTATE UTERUS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Jones metroplasty",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Tompkins metroplasty",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Fetal salvage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Reduction in pregnancy complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Reduction in dysmenorrhea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/3292\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/3292|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?33/40/34439\" title=\"figure 1\">",
"      Mullerian anomalies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?32/62/33774\" title=\"figure 2A\">",
"      Vaginal agenesis rudiment horns",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?25/28/26063\" title=\"figure 2B\">",
"      Unicornuate uter and xtra hornB",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/30/39400\" title=\"figure 3\">",
"      Resectoscope metroplasty",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?24/46/25321\" title=\"figure 4A\">",
"      Jones metroplasty AB",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?27/63/28665\" title=\"figure 4B\">",
"      Jones metroplasty CD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/14/6373\" title=\"figure 4C\">",
"      Jones metroplasty E",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?29/9/29849\" title=\"figure 5A\">",
"      Tompkins metroplasty AB",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?13/9/13466\" title=\"figure 5B\">",
"      Tompkins metroplasty CD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/45/13015\" title=\"figure 5C\">",
"      Tompkins metroplasty E",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/3292|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?0/33/531\" title=\"picture 1A\">",
"      Hemi-uterus1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?22/23/22898\" title=\"picture 1B\">",
"      Hemi-uterus2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?34/22/35172\" title=\"picture 2\">",
"      Fundus of septate uterus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?14/14/14563\" title=\"picture 3A\">",
"      Uterine septum at hysteroscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?23/0/23555\" title=\"picture 3B\">",
"      Wire resection uterine septum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/52/38723\" title=\"picture 3C\">",
"      Unified uterine cavity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/3292|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/32/2572\" title=\"table 1\">",
"      Types of Mullerian anomalies",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/10/5290?source=related_link\">",
"      Choosing the route of delivery after cesarean birth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/0/26633?source=related_link\">",
"      Clinical manifestations and diagnosis of congenital anomalies of the uterus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/3/26679?source=related_link\">",
"      Evaluation of couples with recurrent pregnancy loss",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_21_29015="Effect of exercise on lipid metabolism";
var content_f28_21_29015=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F61616&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F61616&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Effect of exercise on lipid metabolism",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 373px; height: 428px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Schematic representation shows the roles of lipoprotein lipase (LPL) and hepatic triglyceride lipase (HTGL) activities in the regulation of plasma high-density lipoprotein (HDL). In the sedentary state, low LPL and high HTGL activities lead to a decrease in the production of HDL-2 particles due to reduced catabolism of triglyceride (TG)-rich lipoproteins. In contrast, in physically active individuals, LPL activity is high, contributing to the generation of HDL-2 particles; the low activity of HTGL maintains HDL-2 concentration at a higher level than in sedendary individuals.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Despres JP, Lamarche B. J Intern Med 1994; 236:7.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_21_29015=[""].join("\n");
var outline_f28_21_29015=null;
var title_f28_21_29016="Effect of herpes simplex virus on HIV infection: Implications for HIV prevention";
var content_f28_21_29016=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Effect of herpes simplex virus on HIV infection: Implications for HIV prevention",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/21/29016/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/21/29016/contributors\">",
"     Christine Johnston, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/21/29016/contributors\">",
"     Anna Wald, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/21/29016/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/21/29016/contributors\">",
"     Martin S Hirsch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/21/29016/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/21/29016/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/21/29016/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 29, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H4510284\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Herpes simplex virus type 2 (HSV-2) infection is highly prevalent among HIV-infected patients. Whether this association results from similar modes of acquisition or to biologic interactions between the two viruses has been a topic of intense debate.",
"   </p>",
"   <p>",
"    This topic will address interactions between HIV and HSV-2 and the implications for HIV prevention. The natural history, clinical manifestations, diagnosis, and treatment of genital HSV infection in the HIV-infected host are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/52/41799?source=see_link\">",
"     \"Treatment of genital herpes simplex virus type 2 in HIV-infected patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/12/28872?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of genital herpes simplex virus in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H346164\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The discussion below addresses the effect of HSV-2 infection on HIV acquisition and transmission. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2188350\">",
"    <span class=\"h2\">",
"     HIV acquisition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several lines of evidence suggest that prevalent and incident HSV-2 infections increase the risk of HIV acquisition. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H346025\">",
"    <span class=\"h3\">",
"     Prevalent HSV-2 infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epidemiologic studies have shown that HSV-2-seropositive persons have a two- to threefold increased risk of acquiring HIV infection compared with HSV-2-seronegative persons [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29016/abstract/1-5\">",
"     1-5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Mathematical models estimate that in settings of high HSV-2 prevalence, more than 25 percent of incident HIV infections may be attributed to HSV-2 infection [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29016/abstract/6\">",
"     6",
"    </a>",
"    ]. Observational epidemiologic studies support similar findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a meta-analysis of 18 longitudinal studies, HSV-2 infection was associated with 2.7-fold increased risk of HIV acquisition among men (95% CI 1.9-3.9), and a 3.1-fold increased risk among women (95% CI 1.7-5.6), after adjusting for age and sexual behavior [",
"      <a class=\"abstract\" href=\"UTD.htm?28/21/29016/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another meta-analysis of 31 case-control, cohort, and cross-sectional studies, the attributable risk of HIV infection related to HSV-2 ranged from 19 percent where HSV-2 seroprevalence was roughly 20 percent (eg, the United States) to 47 percent where HSV-2 seroprevalence exceeded 80 percent (eg, female sex workers in sub-Saharan Africa) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/21/29016/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4510298\">",
"    <span class=\"h3\">",
"     Incident HSV-2 infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Incident HSV-2 infection is associated with an even greater risk for HIV acquisition than prevalent HSV-2 [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29016/abstract/7-14\">",
"     7-14",
"    </a>",
"    ]. This observation may be related to the greater number of clinical and subclinical reactivation episodes, which occur within the first year of HSV-2 acquisition [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29016/abstract/15-17\">",
"     15-17",
"    </a>",
"    ]. Alternatively, incident HSV-2 and HIV infections may simply be epidemiologic markers for having a sex partner with both infections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2188381\">",
"    <span class=\"h2\">",
"     HIV transmission",
"    </span>",
"    &nbsp;&mdash;&nbsp;HSV infection also increases the risk of HIV transmission.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2188414\">",
"    <span class=\"h3\">",
"     Discordant couples",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term &ldquo;HIV discordant couples&rdquo; is used to describe two sex partners who differ according to their HIV infection status. Carefully performed studies among HIV discordant couples have demonstrated that HSV-2 infection in the source partner increases the probability of HIV transmission by nearly fivefold per coital act compared with those HIV-infected sex partners who are HSV-2-seronegative [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29016/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H346171\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several biologic mechanisms have been proposed to explain the observation that HSV-2 infection may increase the risk of HIV acquisition and transmission, as discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H346053\">",
"    <span class=\"h2\">",
"     Disruption of mucous membranes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sexually transmitted diseases (STDs), both bacterial and viral, are linked to an increased risk of HIV acquisition [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29016/abstract/19\">",
"     19",
"    </a>",
"    ]. Genital ulcerative diseases, such as that caused by HSV-2, lead to disruption of skin or mucous membranes with the formation of microscopic and macroscopic ulcers, which may enhance HIV acquisition by providing direct access to potential target cells [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29016/abstract/20\">",
"     20",
"    </a>",
"    ]. However, HSV-2 serostatus alone is associated with an increased risk of HIV acquisition, independent of the presence of genital ulcers or HSV-2 shedding, suggesting that other factors may play a role [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29016/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H346082\">",
"    <span class=\"h2\">",
"     Local immunologic factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Substantial evidence demonstrates that HSV-2: a) enhances susceptibility to HIV infection among those who are HIV-seronegative and b) increases the risk of HIV transmission from those who are chronically infected with HIV [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29016/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. Local inflammatory changes in the genital tract may explain these phenomena:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Compared with those without HSV-2 infection, HIV-infected patients with HSV-2 infection have enrichment of HSV-2-specific CD4+ and CD8+ T cells and other inflammatory cells in genital secretions [",
"      <a class=\"abstract\" href=\"UTD.htm?28/21/29016/abstract/21,23\">",
"       21,23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In HSV-seropositive patients who are HIV-uninfected, increased numbers of cellular targets of HIV (eg, CD4+ and CD8+ T cells and dendritic cells) with the necessary coreceptors for cellular entry (eg, CCR5) have been demonstrated in the female cervix, the male foreskin, and in tissue from healed genital ulcers months after HSV-2 reactivation [",
"      <a class=\"abstract\" href=\"UTD.htm?28/21/29016/abstract/21,22,24\">",
"       21,22,24",
"      </a>",
"      ]. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2188488\">",
"    <span class=\"h2\">",
"     HIV RNA shedding in HSV genital lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increased HIV RNA shedding among male and female patients with HSV infection may be an important factor contributing to HIV transmission [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29016/abstract/23,25\">",
"     23,25",
"    </a>",
"    ]. For example, studies of women from Kenya, Ghana, the Central African Republic, and Burkina Faso demonstrated that cervicovaginal HIV RNA was detected more frequently, and at higher copy number, in the genital tract of HSV-2-seropositive women with HSV-2-associated ulcers or viral shedding, compared with women without HSV-2 infection [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29016/abstract/26,27\">",
"     26,27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5754473\">",
"    <span class=\"h1\">",
"     HSV THERAPY AND HIV ACQUISITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The epidemiologic data discussed above raise the question as to whether antiviral therapy for HSV-2 infection can reduce HIV acquisition among HIV-seronegative persons. However, two randomized, double-blind, placebo-controlled trials in high-risk HSV-2-positive, HIV-negative women in Tanzania [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29016/abstract/28\">",
"     28",
"    </a>",
"    ] and men who have sex with men (MSM) in North and South America and women in sub-Saharan Africa [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29016/abstract/29\">",
"     29",
"    </a>",
"    ], showed that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    (400 mg twice daily) does not prevent HIV acquisition among HSV-2-seropositive individuals.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H347552\">",
"    <span class=\"h1\">",
"     HSV THERAPY AND HIV TRANSMISSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The observed epidemiologic trends and studies of pathogenesis raise three basic questions. Can viral suppression of HSV-2 with antiviral therapy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lower levels of plasma HIV viremia?",
"     </li>",
"     <li>",
"      Decrease HIV genital shedding?",
"     </li>",
"     <li>",
"      Reduce rates of HIV transmission?",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H275545\">",
"    <span class=\"h2\">",
"     Effect of HSV treatment on HIV replication",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of HSV-2-related genital ulcerative disease can include either: a) chronic suppressive therapy or b) episodic therapy for genital ulcers as they occur. Both approaches have been evaluated for their potential effect on HIV replication and genital HIV shedding. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/52/41799?source=see_link&amp;anchor=H251515427#H251515427\">",
"     \"Treatment of genital herpes simplex virus type 2 in HIV-infected patients\", section on 'Treatment strategies for recurrent disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Clinical trials have shown that daily antiviral therapy for suppression of genital HSV-2 is associated with a decline in plasma HIV viremia [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29016/abstract/30-39\">",
"     30-39",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/44/39622?source=see_link\">",
"       Valacyclovir",
"      </a>",
"      (500 mg twice daily) was associated with a sustained 0.3 to 0.5 log",
"      <sub>",
"       10",
"      </sub>",
"      decrease in HIV plasma RNA levels over three months of follow-up among",
"      <span class=\"nowrap\">",
"       HIV/HSV-2-coinfected",
"      </span>",
"      women who were not taking antiretroviral therapy (ART) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/21/29016/abstract/31,32\">",
"       31,32",
"      </a>",
"      ]. In studies with up to 24 months of follow-up, similar findings have been observed with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"       acyclovir",
"      </a>",
"      among HIV-infected men and women who were coinfected with HSV-2 [",
"      <a class=\"abstract\" href=\"UTD.htm?28/21/29016/abstract/30,33,34\">",
"       30,33,34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In one comparative trial, high-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/44/39622?source=see_link\">",
"       valacyclovir",
"      </a>",
"      (1500 mg twice daily) was associated with a 0.6 log",
"      <sub>",
"       10",
"      </sub>",
"      <span class=\"nowrap\">",
"       copy/mL",
"      </span>",
"      greater decline in HIV RNA levels as compared with standard dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"       acyclovir",
"      </a>",
"      (400 mg twice daily) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/21/29016/abstract/40\">",
"       40",
"      </a>",
"      ]. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The mechanisms that may account for declines of plasma HIV RNA during therapy for HSV-2 infection are unclear. In vitro studies have shown that high, but clinically relevant concentrations of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    may have inhibitory effects against HIV replication [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29016/abstract/41\">",
"     41",
"    </a>",
"    ], and drug exposure leads to emergence of certain mutations within HIV reverse transcriptase [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29016/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. Whether acyclovir directly inhibits HIV replication in vivo at physiologic doses is uncertain, since these particular mutations have not been seen among acyclovir-exposed patients, even after prolonged duration of daily therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29016/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. Alternatively, the reduction in plasma HIV RNA may be mediated by reduced inflammation secondary to HSV suppression, which could lead to a lower number of target cells for HIV.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2190093\">",
"    <span class=\"h2\">",
"     Effect of HSV therapy on HIV genital shedding",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effect of HSV antiviral therapy on HIV genital shedding is less clear. Although daily use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/44/39622?source=see_link\">",
"     valacyclovir",
"    </a>",
"    (500 mg twice daily) has been associated with a decline in frequency and quantity of HIV shedding in",
"    <span class=\"nowrap\">",
"     HIV/HSV-2-coinfected",
"    </span>",
"    men and women [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29016/abstract/32,35,36\">",
"     32,35,36",
"    </a>",
"    ], trials assessing the effect of suppressive therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    have had inconsistent findings [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29016/abstract/33,34,46\">",
"     33,34,46",
"    </a>",
"    ]. Furthermore, episodic acyclovir therapy (400 mg three times daily for five days) for recurrent HSV-2 disease reduced the frequency and quantity of HIV genital shedding among men with genital ulcers [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29016/abstract/47\">",
"     47",
"    </a>",
"    ], but had no effect on HIV genital shedding among women [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29016/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2540913\">",
"    <span class=\"h2\">",
"     HSV suppression and risk of HIV transmission",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite the overwhelming epidemiologic and biologic evidence for an association between HSV-2 infection and HIV infection, HSV-2 suppressive therapy does not appear to decrease the risk of HIV transmission [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29016/abstract/30\">",
"     30",
"    </a>",
"    ]. A controlled trial (Partners in Prevention",
"    <span class=\"nowrap\">",
"     HSV/HIV",
"    </span>",
"    Transmission Study) was conducted in 14 sites in Africa to evaluate whether suppressive antiviral therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    would reduce HIV transmission among 3408 HIV discordant heterosexual couples [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29016/abstract/30\">",
"     30",
"    </a>",
"    ].",
"    <span class=\"nowrap\">",
"     HIV/HSV-coinfected",
"    </span>",
"    partners were randomly assigned to acyclovir (400 mg twice daily) or placebo. All eligible patients had a CD4 cell count &gt;250",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    and thus did not meet national guidelines for ART at the time the study was performed. The following summary illustrates the main findings [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29016/abstract/30\">",
"     30",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"       Acyclovir",
"      </a>",
"      reduced the occurrence of genital ulcers by 73 percent and reduced HIV RNA levels by 0.25 log",
"      <sub>",
"       10",
"      </sub>",
"      <span class=\"nowrap\">",
"       copies/mL",
"      </span>",
"      in the",
"      <span class=\"nowrap\">",
"       HIV/HSV-coinfected",
"      </span>",
"      partners.",
"     </li>",
"     <li>",
"      However, the numbers of HIV transmission events that were linked (as determined by viral sequencing) were similar in the intervention and placebo arms.",
"     </li>",
"     <li>",
"      No serious adverse events were observed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2189330\">",
"    <span class=\"h1\">",
"     THE IMPACT OF HSV-2 INFECTION ON HIV DISEASE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2189567\">",
"    <span class=\"h2\">",
"     Impact of HSV-2 on plasma HIV RNA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies have shown that HSV-2 infection is associated with increased levels of plasma HIV RNA among HIV-1 chronically-infected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29016/abstract/26,49,50\">",
"     26,49,50",
"    </a>",
"    ]. In a small study of HIV-infected patients with a history of recurrent HSV-2 genital ulcers, an acute outbreak of genital ulcers was associated with a 3.4-fold rise in plasma HIV RNA that persisted above baseline levels for more than one month [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29016/abstract/49\">",
"     49",
"    </a>",
"    ]. In contrast, levels of HIV RNA declined with initiation of HSV antiviral therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29016/abstract/50\">",
"     50",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    However, there are conflicting data as to whether HSV-2 infection is associated with increased plasma HIV RNA among patients with acute HIV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29016/abstract/51-53\">",
"     51-53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2189594\">",
"    <span class=\"h3\">",
"     Mechanisms of enhanced HIV replication",
"    </span>",
"    &nbsp;&mdash;&nbsp;In vitro studies have highlighted potential mechanisms through which HSV may promote HIV replication in chronically infected patients:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      HSV-2 can activate HIV from an inactive (latent) state [",
"      <a class=\"abstract\" href=\"UTD.htm?28/21/29016/abstract/54,55\">",
"       54,55",
"      </a>",
"      ]. HSV upregulates cellular proteins, which are associated with transcriptional activation of HIV-1 [",
"      <a class=\"abstract\" href=\"UTD.htm?28/21/29016/abstract/23,54-59\">",
"       23,54-59",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Within CD4+ T cells, HSV-2 upregulates HIV replication and gene expression [",
"      <a class=\"abstract\" href=\"UTD.htm?28/21/29016/abstract/23,58\">",
"       23,58",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      HSV-2 genital ulcers demonstrate an influx of HSV-specific CD8+ T-cells, which contribute to HSV-2 clearance [",
"      <a class=\"abstract\" href=\"UTD.htm?28/21/29016/abstract/60\">",
"       60",
"      </a>",
"      ]. These cells persist and accumulate in the dermal skin [",
"      <a class=\"abstract\" href=\"UTD.htm?28/21/29016/abstract/61\">",
"       61",
"      </a>",
"      ] and may contribute to local immune activation [",
"      <a class=\"abstract\" href=\"UTD.htm?28/21/29016/abstract/62\">",
"       62",
"      </a>",
"      ], which is associated with elevated levels of proinflammatory cytokines and CD4 cell decline [",
"      <a class=\"abstract\" href=\"UTD.htm?28/21/29016/abstract/63\">",
"       63",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/34/5674?source=see_link\">",
"       \"Immunology of HIV-1 infection\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2189227\">",
"    <span class=\"h2\">",
"     Impact of HSV-2 on T cell recovery",
"    </span>",
"    &nbsp;&mdash;&nbsp;The impact of HSV-2 infection on CD4+ T cells has been examined. The observational data discussed below do not suggest a major effect of HSV coinfection on CD4 cell trajectories [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29016/abstract/53,64\">",
"     53,64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One study evaluated the impact of HSV-2 status on the immunologic status and HIV viral load among 186 HIV seroconverters [",
"      <a class=\"abstract\" href=\"UTD.htm?28/21/29016/abstract/53\">",
"       53",
"      </a>",
"      ]. No relationship between HSV-2 serostatus and plasma HIV-1 RNA levels were seen. In contrast, persons with",
"      <span class=\"nowrap\">",
"       HIV-1/HSV-2",
"      </span>",
"      coinfection had significantly higher CD4+ T cell counts compared with those with HIV-1 infection alone, after adjustment for HIV-1 RNA levels.",
"     </li>",
"     <li>",
"      In an observational study among 1938 chronically HIV-infected women with HSV-2 infection, there was a modest relationship between the frequency of HSV reactivation episodes and CD4 cell loss [",
"      <a class=\"abstract\" href=\"UTD.htm?28/21/29016/abstract/65\">",
"       65",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2541616\">",
"    <span class=\"h2\">",
"     HSV-2 antiviral therapy and HIV progression",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 1998 meta-analysis of clinical trials, performed prior to the widespread availability of potent ART, showed that high-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    (&ge;3200",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    was associated with reduced overall mortality (HR 0.78, 95% CI 0.65-0.93) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29016/abstract/66\">",
"     66",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    The effect of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    administration (400 mg twice daily) on HIV disease progression was investigated in a placebo-controlled clinical trial of 440",
"    <span class=\"nowrap\">",
"     HIV/HSV-2",
"    </span>",
"    dually-infected treatment-na&iuml;ve adults with CD4 cell counts ranging between 300 and 400",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29016/abstract/67\">",
"     67",
"    </a>",
"    ]. The primary outcome was a CD4 cell count &lt;250",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    or the initiation of ART for WHO stage 4 disease (eg, presence of HIV wasting or an opportunistic infection). The trial demonstrated that patients with a baseline plasma viral load &gt;50,000",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    who were assigned acyclovir had a significant reduction in HIV clinical progression compared with those assigned placebo (HR = 0.62, 95% CI 0.43-0.96), whereas no benefit was seen among those with lower levels of HIV RNA (0.90, 95% CI 0.54-1.5).",
"   </p>",
"   <p>",
"    In the Partners in Prevention trial discussed above, the primary aim was to determine whether",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    was associated with a reduced risk of HIV transmission. After the trial was underway, the investigators added an analysis to evaluate the effect of acyclovir on HIV disease progression among those patients who were not yet ART eligible [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29016/abstract/39\">",
"     39",
"    </a>",
"    ]. HIV disease progression was defined by a primary composite endpoint of: a) first occurrence of a CD4 cell count &lt;200",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     ,",
"    </span>",
"    b) initiation of antiretroviral therapy, or c) non-trauma related death. At baseline, the median CD4 cell count was 462",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    and the median HIV-1 plasma RNA was 4.1 log",
"    <sub>",
"     10",
"    </sub>",
"    copies per microL. The following findings were observed:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A total of 608 patients reached the primary composite endpoint; patients in the intervention arm had a 16 percent risk reduction of HIV disease progression compared with placebo (hazard ratio 0.84, 95% CI 0.71-0.98).",
"     </li>",
"     <li>",
"      A subgroup analysis among those with a CD4 cell count of &gt;350",
"      <span class=\"nowrap\">",
"       cells/mm",
"       <sup>",
"        3",
"       </sup>",
"      </span>",
"      also showed a clinical benefit in the patients on the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"       acyclovir",
"      </a>",
"      arm. This threshold was analyzed because the World Health Organization (WHO) had changed the indication to start ART to a CD4 cell count of &lt;350",
"      <span class=\"nowrap\">",
"       cells/mm",
"       <sup>",
"        3",
"       </sup>",
"      </span>",
"      during the course of the trial.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    More studies are needed to define the potential benefit of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    in the",
"    <span class=\"nowrap\">",
"     HIV/HSV-2-coinfected",
"    </span>",
"    patient who does not meet ART treatment criteria in resource-limited settings [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29016/abstract/68\">",
"     68",
"    </a>",
"    ]. However, combination ART, although more costly than acyclovir therapy, would be expected to have a more significant impact on overall HIV disease progression than HSV suppressive therapy. Finally, ART also decreases the risk of HIV transmission, whereas HSV prophylaxis does not [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29016/abstract/38\">",
"     38",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/6/39018?source=see_link\">",
"     \"The impact of antiretroviral therapy on morbidity and mortality of HIV infection in resource-limited settings\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/24/19848?source=see_link\">",
"     \"HIV treatment as prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4510276\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Herpes simplex virus type 2 infection is highly prevalent among HIV-infected patients. Whether this association results from similar modes of acquisition or to biologic interactions between the two viruses has been a topic of intense debate. (See",
"      <a class=\"local\" href=\"#H4510284\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Epidemiologic studies suggest that incident and prevalent genital herpes simplex virus type 2 (HSV-2) increases the risk of HIV acquisition. (See",
"      <a class=\"local\" href=\"#H346164\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      HSV-2 infection may contribute to risk of HIV acquisition through disruption of genital mucosal barriers or alteration of local immunologic factors.",
"     </li>",
"     <li>",
"      HSV-2 infection may contribute to risk of HIV transmission by increasing HIV genital shedding in men and women, particularly at sites of HSV-2 genital ulcers. (See",
"      <a class=\"local\" href=\"#H346171\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      HSV-2-related genital ulcerative disease is associated with increased levels of HIV plasma viremia among HIV-1 chronically-infected patients compared with patients with HIV infection alone. (See",
"      <a class=\"local\" href=\"#H2189567\">",
"       'Impact of HSV-2 on plasma HIV RNA'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinical trials have shown that antiviral therapy for chronic suppression of genital HSV-2 infection is associated with a reduced level of HIV viremia. (See",
"      <a class=\"local\" href=\"#H275545\">",
"       'Effect of HSV treatment on HIV replication'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinical trial data in diverse patient populations in both resource-rich and resource-limited settings do not support a role for HSV-2 suppressive therapy in preventing HIV acquisition among HSV-2 seropositive HIV-uninfected patients. (See",
"      <a class=\"local\" href=\"#H5754473\">",
"       'HSV therapy and HIV acquisition'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Despite epidemiologic and biologic evidence for an association between HSV-2 infection and HIV infection, clinical trials of HSV-2 suppressive therapy have not demonstrated protection against HIV transmission among HIV discordant couples in Africa in which the potential source partner received daily anti-HSV therapy. (See",
"      <a class=\"local\" href=\"#H2540913\">",
"       'HSV suppression and risk of HIV transmission'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Suppressive antiviral therapy for HSV-2 infection may be associated with lower rates of HIV disease progression among HIV-infected patients with CD4 cell counts &lt;350",
"      <span class=\"nowrap\">",
"       cells/mm",
"       <sup>",
"        3",
"       </sup>",
"      </span>",
"      who are not receiving antiretroviral therapy. However, confirmatory data are needed to better define the role of HSV suppression in delaying HIV disease progression among",
"      <span class=\"nowrap\">",
"       HIV/HSV-2-coinfected",
"      </span>",
"      patients. (See",
"      <a class=\"local\" href=\"#H2541616\">",
"       'HSV-2 antiviral therapy and HIV progression'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29016/abstract/1\">",
"      Weiss HA, Buv&eacute; A, Robinson NJ, et al. The epidemiology of HSV-2 infection and its association with HIV infection in four urban African populations. AIDS 2001; 15 Suppl 4:S97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29016/abstract/2\">",
"      Auvert B, Buv&eacute; A, Ferry B, et al. Ecological and individual level analysis of risk factors for HIV infection in four urban populations in sub-Saharan Africa with different levels of HIV infection. AIDS 2001; 15 Suppl 4:S15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29016/abstract/3\">",
"      Freeman EE, Weiss HA, Glynn JR, et al. Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. AIDS 2006; 20:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29016/abstract/4\">",
"      Wald A, Link K. Risk of human immunodeficiency virus infection in herpes simplex virus type 2-seropositive persons: a meta-analysis. J Infect Dis 2002; 185:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29016/abstract/5\">",
"      Baeten JM, Benki S, Chohan V, et al. Hormonal contraceptive use, herpes simplex virus infection, and risk of HIV-1 acquisition among Kenyan women. AIDS 2007; 21:1771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29016/abstract/6\">",
"      Abu-Raddad LJ, Magaret AS, Celum C, et al. Genital herpes has played a more important role than any other sexually transmitted infection in driving HIV prevalence in Africa. PLoS One 2008; 3:e2230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29016/abstract/7\">",
"      Ramjee G, Williams B, Gouws E, et al. The impact of incident and prevalent herpes simplex virus-2 infection on the incidence of HIV-1 infection among commercial sex workers in South Africa. J Acquir Immune Defic Syndr 2005; 39:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29016/abstract/8\">",
"      Kapiga SH, Sam NE, Bang H, et al. The role of herpes simplex virus type 2 and other genital infections in the acquisition of HIV-1 among high-risk women in northern Tanzania. J Infect Dis 2007; 195:1260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29016/abstract/9\">",
"      del Mar Pujades Rodr&iacute;guez M, Obasi A, Mosha F, et al. Herpes simplex virus type 2 infection increases HIV incidence: a prospective study in rural Tanzania. AIDS 2002; 16:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29016/abstract/10\">",
"      Tobian AA, Ssempijja V, Kigozi G, et al. Incident HIV and herpes simplex virus type 2 infection among men in Rakai, Uganda. AIDS 2009; 23:1589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29016/abstract/11\">",
"      Reynolds SJ, Risbud AR, Shepherd ME, et al. Recent herpes simplex virus type 2 infection and the risk of human immunodeficiency virus type 1 acquisition in India. J Infect Dis 2003; 187:1513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29016/abstract/12\">",
"      Sobngwi-Tambekou J, Taljaard D, Lissouba P, et al. Effect of HSV-2 serostatus on acquisition of HIV by young men: results of a longitudinal study in Orange Farm, South Africa. J Infect Dis 2009; 199:958.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29016/abstract/13\">",
"      Brown JM, Wald A, Hubbard A, et al. Incident and prevalent herpes simplex virus type 2 infection increases risk of HIV acquisition among women in Uganda and Zimbabwe. AIDS 2007; 21:1515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29016/abstract/14\">",
"      Sanchez J, Lama JR, Peinado J, et al. High HIV and ulcerative sexually transmitted infection incidence estimates among men who have sex with men in Peru: awaiting for an effective preventive intervention. J Acquir Immune Defic Syndr 2009; 51 Suppl 1:S47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29016/abstract/15\">",
"      Benedetti J, Corey L, Ashley R. Recurrence rates in genital herpes after symptomatic first-episode infection. Ann Intern Med 1994; 121:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29016/abstract/16\">",
"      Wald A, Zeh J, Selke S, et al. Virologic characteristics of subclinical and symptomatic genital herpes infections. N Engl J Med 1995; 333:770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29016/abstract/17\">",
"      Koelle DM, Benedetti J, Langenberg A, Corey L. Asymptomatic reactivation of herpes simplex virus in women after the first episode of genital herpes. Ann Intern Med 1992; 116:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29016/abstract/18\">",
"      Corey L, Wald A, Celum CL, Quinn TC. The effects of herpes simplex virus-2 on HIV-1 acquisition and transmission: a review of two overlapping epidemics. J Acquir Immune Defic Syndr 2004; 35:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29016/abstract/19\">",
"      Kaplan JE, Benson C, Holmes KH, et al. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 2009; 58:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29016/abstract/20\">",
"      Gray RH, Wawer MJ, Brookmeyer R, et al. Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda. Lancet 2001; 357:1149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29016/abstract/21\">",
"      Rebbapragada A, Wachihi C, Pettengell C, et al. Negative mucosal synergy between Herpes simplex type 2 and HIV in the female genital tract. AIDS 2007; 21:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29016/abstract/22\">",
"      Johnson KE, Redd AD, Quinn TC, et al. Effects of HIV-1 and herpes simplex virus type 2 infection on lymphocyte and dendritic cell density in adult foreskins from Rakai, Uganda. J Infect Dis 2011; 203:602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29016/abstract/23\">",
"      Albrecht MA, DeLuca NA, Byrn RA, et al. The herpes simplex virus immediate-early protein, ICP4, is required to potentiate replication of human immunodeficiency virus in CD4+ lymphocytes. J Virol 1989; 63:1861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29016/abstract/24\">",
"      Zhu J, Hladik F, Woodward A, et al. Persistence of HIV-1 receptor-positive cells after HSV-2 reactivation is a potential mechanism for increased HIV-1 acquisition. Nat Med 2009; 15:886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29016/abstract/25\">",
"      Schacker T, Ryncarz AJ, Goddard J, et al. Frequent recovery of HIV-1 from genital herpes simplex virus lesions in HIV-1-infected men. JAMA 1998; 280:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29016/abstract/26\">",
"      Nagot N, Ouedraogo A, Konate I, et al. Roles of clinical and subclinical reactivated herpes simplex virus type 2 infection and human immunodeficiency virus type 1 (HIV-1)-induced immunosuppression on genital and plasma HIV-1 levels. J Infect Dis 2008; 198:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29016/abstract/27\">",
"      Baeten JM, McClelland RS, Corey L, et al. Vitamin A supplementation and genital shedding of herpes simplex virus among HIV-1-infected women: a randomized clinical trial. J Infect Dis 2004; 189:1466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29016/abstract/28\">",
"      Watson-Jones D, Weiss HA, Rusizoka M, et al. Effect of herpes simplex suppression on incidence of HIV among women in Tanzania. N Engl J Med 2008; 358:1560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29016/abstract/29\">",
"      Celum C, Wald A, Hughes J, et al. Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebo-controlled trial. Lancet 2008; 371:2109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29016/abstract/30\">",
"      Celum C, Wald A, Lingappa JR, et al. Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2. N Engl J Med 2010; 362:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29016/abstract/31\">",
"      Nagot N, Ou&eacute;draogo A, Foulongne V, et al. Reduction of HIV-1 RNA levels with therapy to suppress herpes simplex virus. N Engl J Med 2007; 356:790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29016/abstract/32\">",
"      Baeten JM, Strick LB, Lucchetti A, et al. Herpes simplex virus (HSV)-suppressive therapy decreases plasma and genital HIV-1 levels in HSV-2/HIV-1 coinfected women: a randomized, placebo-controlled, cross-over trial. J Infect Dis 2008; 198:1804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29016/abstract/33\">",
"      Dunne EF, Whitehead S, Sternberg M, et al. Suppressive acyclovir therapy reduces HIV cervicovaginal shedding in HIV- and HSV-2-infected women, Chiang Rai, Thailand. J Acquir Immune Defic Syndr 2008; 49:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29016/abstract/34\">",
"      Delany S, Mlaba N, Clayton T, et al. Impact of aciclovir on genital and plasma HIV-1 RNA in HSV-2/HIV-1 co-infected women: a randomized placebo-controlled trial in South Africa. AIDS 2009; 23:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29016/abstract/35\">",
"      Ouedraogo A, Nagot N, Vergne L, et al. Impact of suppressive herpes therapy on genital HIV-1 RNA among women taking antiretroviral therapy: a randomized controlled trial. AIDS 2006; 20:2305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29016/abstract/36\">",
"      Zuckerman RA, Lucchetti A, Whittington WL, et al. HSV suppression reduces seminal HIV-1 levels in HIV-1/HSV-2 co-infected men who have sex with men. AIDS 2009; 23:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29016/abstract/37\">",
"      Kim HN, Wang J, Hughes J, et al. Effect of acyclovir on HIV-1 set point among herpes simplex virus type 2-seropositive persons during early HIV-1 infection. J Infect Dis 2010; 202:734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29016/abstract/38\">",
"      Ludema C, Cole SR, Poole C, et al. Meta-analysis of randomized trials on the association of prophylactic acyclovir and HIV-1 viral load in individuals coinfected with herpes simplex virus-2. AIDS 2011; 25:1265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29016/abstract/39\">",
"      Lingappa JR, Baeten JM, Wald A, et al. Daily acyclovir for HIV-1 disease progression in people dually infected with HIV-1 and herpes simplex virus type 2: a randomised placebo-controlled trial. Lancet 2010; 375:824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29016/abstract/40\">",
"      Mugwanya K, Baeten JM, Mugo NR, et al. High-dose valacyclovir HSV-2 suppression results in greater reduction in plasma HIV-1 levels compared with standard dose acyclovir among HIV-1/HSV-2 coinfected persons: a randomized, crossover trial. J Infect Dis 2011; 204:1912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29016/abstract/41\">",
"      Vanpouille C, Lisco A, Introini A, et al. Exploiting the anti-HIV-1 activity of acyclovir: suppression of primary and drug-resistant HIV isolates and potentiation of the activity by ribavirin. Antimicrob Agents Chemother 2012; 56:2604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29016/abstract/42\">",
"      McMahon MA, Siliciano JD, Lai J, et al. The antiherpetic drug acyclovir inhibits HIV replication and selects the V75I reverse transcriptase multidrug resistance mutation. J Biol Chem 2008; 283:31289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29016/abstract/43\">",
"      Lisco A, Vanpouille C, Tchesnokov EP, et al. Acyclovir is activated into a HIV-1 reverse transcriptase inhibitor in herpesvirus-infected human tissues. Cell Host Microbe 2008; 4:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29016/abstract/44\">",
"      LeGoff J, Tanton C, Delaugerre C, et al. No selection of nucleoside reverse transcriptase inhibitor resistance associated mutations by acyclovir suppressive therapy in herpes simplex virus-2/HIV-1 dually infected persons. AIDS 2010; 24:2595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29016/abstract/45\">",
"      Baeten JM, Lingappa J, Beck I, et al. Herpes simplex virus type 2 suppressive therapy with acyclovir or valacyclovir does not select for specific HIV-1 resistance in HIV-1/HSV-2 dually infected persons. J Infect Dis 2011; 203:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29016/abstract/46\">",
"      Cowan FM, Pascoe SJ, Barlow KL, et al. A randomised placebo-controlled trial to explore the effect of suppressive therapy with acyclovir on genital shedding of HIV-1 and herpes simplex virus type 2 among Zimbabwean sex workers. Sex Transm Infect 2008; 84:548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29016/abstract/47\">",
"      Paz-Bailey G, Sternberg M, Puren AJ, et al. Improvement in healing and reduction in HIV shedding with episodic acyclovir therapy as part of syndromic management among men: a randomized, controlled trial. J Infect Dis 2009; 200:1039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29016/abstract/48\">",
"      Mayaud P, Legoff J, Weiss HA, et al. Impact of acyclovir on genital and plasma HIV-1 RNA, genital herpes simplex virus type 2 DNA, and ulcer healing among HIV-1-infected African women with herpes ulcers: a randomized placebo-controlled trial. J Infect Dis 2009; 200:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29016/abstract/49\">",
"      Mole L, Ripich S, Margolis D, Holodniy M. The impact of active herpes simplex virus infection on human immunodeficiency virus load. J Infect Dis 1997; 176:766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29016/abstract/50\">",
"      Schacker T, Zeh J, Hu H, et al. Changes in plasma human immunodeficiency virus type 1 RNA associated with herpes simplex virus reactivation and suppression. J Infect Dis 2002; 186:1718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29016/abstract/51\">",
"      Gray RH, Li X, Wawer MJ, et al. Determinants of HIV-1 load in subjects with early and later HIV infections, in a general-population cohort of Rakai, Uganda. J Infect Dis 2004; 189:1209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29016/abstract/52\">",
"      Cachay ER, Frost SD, Richman DD, et al. Herpes simplex virus type 2 infection does not influence viral dynamics during early HIV-1 infection. J Infect Dis 2007; 195:1270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29016/abstract/53\">",
"      Barbour JD, Sauer MM, Sharp ER, et al. HIV-1/HSV-2 co-infected adults in early HIV-1 infection have elevated CD4+ T cell counts. PLoS One 2007; 2:e1080.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29016/abstract/54\">",
"      Golden MP, Kim S, Hammer SM, et al. Activation of human immunodeficiency virus by herpes simplex virus. J Infect Dis 1992; 166:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29016/abstract/55\">",
"      Chapman CJ, Harris JD, Collins MK, Latchman DS. A recombinant HIV provirus is synergistically activated by the HIV Tat protein and the HSV IE1 protein but not by the HSV IE3 protein. AIDS 1991; 5:945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29016/abstract/56\">",
"      Margolis DM, Rabson AB, Straus SE, Ostrove JM. Transactivation of the HIV-1 LTR by HSV-1 immediate-early genes. Virology 1992; 186:788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29016/abstract/57\">",
"      Mosca JD, Bednarik DP, Raj NB, et al. Activation of human immunodeficiency virus by herpesvirus infection: identification of a region within the long terminal repeat that responds to a trans-acting factor encoded by herpes simplex virus 1. Proc Natl Acad Sci U S A 1987; 84:7408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29016/abstract/58\">",
"      Diaz JJ, Dodon MD, Schaerer-Uthurralt N, et al. Post-transcriptional transactivation of human retroviral envelope glycoprotein expression by herpes simplex virus Us11 protein. Nature 1996; 379:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29016/abstract/59\">",
"      Margolis DM, Ostrove JM, Straus SE. HSV-1 activation of HIV-1 transcription is augmented by a cellular protein that binds near the initiator element. Virology 1993; 192:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29016/abstract/60\">",
"      Koelle DM, Posavad CM, Barnum GR, et al. Clearance of HSV-2 from recurrent genital lesions correlates with infiltration of HSV-specific cytotoxic T lymphocytes. J Clin Invest 1998; 101:1500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29016/abstract/61\">",
"      Zhu J, Koelle DM, Cao J, et al. Virus-specific CD8+ T cells accumulate near sensory nerve endings in genital skin during subclinical HSV-2 reactivation. J Exp Med 2007; 204:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29016/abstract/62\">",
"      Sheth PM, Sunderji S, Shin LY, et al. Coinfection with herpes simplex virus type 2 is associated with reduced HIV-specific T cell responses and systemic immune activation. J Infect Dis 2008; 197:1394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29016/abstract/63\">",
"      Van de Perre P, Segondy M, Foulongne V, et al. Herpes simplex virus and HIV-1: deciphering viral synergy. Lancet Infect Dis 2008; 8:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29016/abstract/64\">",
"      Hoots BE, Hudgens MG, Cole SR, et al. Lack of association of herpes simplex virus type 2 seropositivity with the progression of HIV infection in the HERS cohort. Am J Epidemiol 2011; 173:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29016/abstract/65\">",
"      Aumakhan B, Gaydos CA, Quinn TC, et al. Clinical reactivations of herpes simplex virus type 2 infection and human immunodeficiency virus disease progression markers. PLoS One 2010; 5:e9973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29016/abstract/66\">",
"      Ioannidis JP, Collier AC, Cooper DA, et al. Clinical efficacy of high-dose acyclovir in patients with human immunodeficiency virus infection: a meta-analysis of randomized individual patient data. J Infect Dis 1998; 178:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29016/abstract/67\">",
"      Reynolds SJ, Makumbi F, Newell K, et al. Effect of daily aciclovir on HIV disease progression in individuals in Rakai, Uganda, co-infected with HIV-1 and herpes simplex virus type 2: a randomised, double-blind placebo-controlled trial. Lancet Infect Dis 2012; 12:441.",
"     </a>",
"    </li>",
"    <li>",
"     file://whqlibdoc.who.int/publications/2010/9789241599764_eng.pdf (Accessed on September 27, 2010). (Accessed on September 09, 2011).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14014 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-E2305D93BD-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_21_29016=[""].join("\n");
var outline_f28_21_29016=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H4510276\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4510284\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H346164\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2188350\">",
"      HIV acquisition",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H346025\">",
"      - Prevalent HSV-2 infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4510298\">",
"      - Incident HSV-2 infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2188381\">",
"      HIV transmission",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2188414\">",
"      - Discordant couples",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H346171\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H346053\">",
"      Disruption of mucous membranes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H346082\">",
"      Local immunologic factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2188488\">",
"      HIV RNA shedding in HSV genital lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5754473\">",
"      HSV THERAPY AND HIV ACQUISITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H347552\">",
"      HSV THERAPY AND HIV TRANSMISSION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H275545\">",
"      Effect of HSV treatment on HIV replication",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2190093\">",
"      Effect of HSV therapy on HIV genital shedding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2540913\">",
"      HSV suppression and risk of HIV transmission",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2189330\">",
"      THE IMPACT OF HSV-2 INFECTION ON HIV DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2189567\">",
"      Impact of HSV-2 on plasma HIV RNA",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2189594\">",
"      - Mechanisms of enhanced HIV replication",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2189227\">",
"      Impact of HSV-2 on T cell recovery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2541616\">",
"      HSV-2 antiviral therapy and HIV progression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4510276\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/12/28872?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of genital herpes simplex virus in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/24/19848?source=related_link\">",
"      HIV treatment as prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/34/5674?source=related_link\">",
"      Immunology of HIV-1 infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/6/39018?source=related_link\">",
"      The impact of antiretroviral therapy on morbidity and mortality of HIV infection in resource-limited settings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/52/41799?source=related_link\">",
"      Treatment of genital herpes simplex virus type 2 in HIV-infected patients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_21_29017="Invasive UC squamous diff";
var content_f28_21_29017=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F69814&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F69814&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Invasive urothelial carcinoma with squamous differentiation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The presence of intercellular bridges and focal keratinization can be easily appreciated (20x).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Cristina Magi-Galluzzi, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_21_29017=[""].join("\n");
var outline_f28_21_29017=null;
var title_f28_21_29018="Antifungal susceptibility testing";
var content_f28_21_29018=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Antifungal susceptibility testing",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/21/29018/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/21/29018/contributors\">",
"     Michael A Pfaller, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/21/29018/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/21/29018/contributors\">",
"     Carol A Kauffman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/21/29018/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/21/29018/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/21/29018/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 10, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The need for reproducible, clinically relevant antifungal susceptibility testing has been prompted by the increasing number of invasive fungal infections, the expanding use of new and established antifungal agents, and recognition of antifungal resistance as an important clinical problem [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29018/abstract/1-4\">",
"     1-4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The collaborative efforts of numerous investigators and the Clinical and Laboratory Standards Institute (CLSI, formerly National Committee for Clinical Laboratory Standards [NCCLS]) Subcommittee on Antifungal Susceptibility Testing have generated consensus documents describing standardized methods for broth- and agar-based antifungal susceptibility testing [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29018/abstract/5-10\">",
"     5-10",
"    </a>",
"    ]. As a result, in vitro antifungal susceptibility testing plays an increasingly important role in guiding therapeutic decision making, as an aid in drug development studies, and as a means of tracking the development of antifungal resistance in epidemiologic studies [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29018/abstract/3,11,12\">",
"     3,11,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An overview of antifungal susceptibility testing will be presented here. The pharmacology and use of antifungal agents for the treatment of specific fungal infections are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36938?source=see_link\">",
"     \"Pharmacology of azoles\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/41/15001?source=see_link\">",
"     \"Pharmacology of amphotericin B\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/11/43190?source=see_link\">",
"     \"Pharmacology of flucytosine (5-FC)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/13/29914?source=see_link\">",
"     \"Treatment of candidemia and invasive candidiasis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/18/28970?source=see_link\">",
"     \"Treatment and prevention of invasive aspergillosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/46/6890?source=see_link\">",
"     \"Mucormycosis (zygomycosis)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/18/6439?source=see_link\">",
"     \"Mycology, pathogenesis, and epidemiology of Fusarium infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An overview of antibacterial susceptibility testing is also presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/5/17495?source=see_link\">",
"     \"Overview of antibacterial susceptibility testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Rationale",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary objective of in vitro susceptibility testing is to predict the impact of administration of the tested agent on the outcome of infection caused by the tested organism or similar organisms [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29018/abstract/3,13\">",
"     3,13",
"    </a>",
"    ]. In this way, antifungal testing is performed for the same reasons that antibacterial testing is performed [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29018/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      To provide a reliable estimate of the relative activities of two or more antimicrobial agents against the pathogen of interest",
"     </li>",
"     <li>",
"      To correlate with in vivo activity and to predict the likely outcome of therapy",
"     </li>",
"     <li>",
"      To provide a quantitative means by which to survey the development of resistance among a normally susceptible population of organisms",
"     </li>",
"     <li>",
"      To predict the therapeutic potential and spectrum of activity of newly developed investigational agents",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the clinical microbiology laboratory, the focus of testing is directed towards a specific clinical isolate causing infection in an individual patient. Studies examining the clinical use of antifungal susceptibility testing have shown that when such testing is available onsite, clinicians find the results helpful and frequently alter therapy based on the results [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29018/abstract/14-18\">",
"     14-18",
"    </a>",
"    ]. As an example, one study found that susceptibility testing of Candida glabrata isolates results in lower overall treatment costs, based on de-escalation in therapy from an expensive echinocandin to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    for patients with documented fluconazole-susceptible C. glabrata bloodstream infection [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29018/abstract/15\">",
"     15",
"    </a>",
"    ]. Routine antifungal susceptibility testing can serve as an adjunct in the treatment of candidemia in the same way that antibacterial testing aids in the treatment of bacterial infections [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29018/abstract/3,19,20\">",
"     3,19,20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Limitations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prediction of outcome in a clinical infection from results obtained in an artificial and well-defined matrix (in vitro susceptibility test) is an inherently error-prone process in which only modest degrees of correlation can be expected [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29018/abstract/3,13,21,22\">",
"     3,13,21,22",
"    </a>",
"    ]. Decades of experience with antibacterial susceptibility testing confirm the limited extent of in vitro-in vivo correlation that can be achieved [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29018/abstract/3,23-25\">",
"     3,23-25",
"    </a>",
"    ]. Just as in vitro resistance does not always predict clinical failure, so in vitro susceptibility does not ensure successful therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29018/abstract/3,26\">",
"     3,26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Clinical relevance",
"    </span>",
"    &nbsp;&mdash;&nbsp;In order to be useful clinically, in vitro susceptibility testing of antimicrobial agents should reliably predict the in vivo response to therapy. However, the in vitro susceptibility of an infecting organism to the antimicrobial agent is only one of several factors that may influence the likelihood that therapy will be successful [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29018/abstract/3,12,26-28\">",
"     3,12,26-28",
"    </a>",
"    ]. Factors related to the host immune response",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the underlying disease, drug pharmacokinetics and pharmacodynamics, drug interactions, and factors related to the virulence of the infecting organism and its interaction with both the host and the antimicrobial agent administered all influence the outcome of treatment of an infection [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29018/abstract/3,12,26\">",
"     3,12,26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Definitions",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Minimum inhibitory concentration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The minimum inhibitory concentration (MIC) is the lowest concentration of an antimicrobial agent that inhibits the growth of fungi, as established by a standardized endpoint.",
"   </p>",
"   <p>",
"    The MIC50 is the concentration of an antimicrobial agent at which 50 percent of the organisms tested are inhibited. The MIC90 is the concentration of an antimicrobial agent at which 90 percent of the organisms tested are inhibited.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Minimum effective concentration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The minimum effective concentration (MEC) is defined as the lowest concentration of an antifungal agent that results in growth of fungi producing conspicuously aberrant growth. Aberrant growth of hyphae is defined as small, round, compact microcolonies compared with the matt of hyphal growth in the control well that does not contain an antifungal agent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H906841683\">",
"    <span class=\"h3\">",
"     Clinical breakpoints",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical interpretive MIC breakpoints for in vitro susceptibility testing are used to indicate those isolates that are likely to respond to treatment with a given antimicrobial agent administered using the approved dosing regimen for that agent [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29018/abstract/26,29\">",
"     26,29",
"    </a>",
"    ]. The Clinical and Laboratory Standards Institute (CLSI) Subcommittee on Antifungal Susceptibility Testing establishes species-specific clinical breakpoints for the systemically active antifungal agents [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29018/abstract/27,30,31\">",
"     27,30,31",
"    </a>",
"    ]. The clinical breakpoints serve as criteria that not only predict clinical outcome but also improve the sensitivity of the CLSI methods to detect emerging resistance associated with acquired or mutational resistance mechanisms. The clinical breakpoints sort isolates into categories of susceptible (S), susceptible dose-dependent (SDD), intermediate (I), and resistant (R).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1471001798\">",
"    <span class=\"h3\">",
"     Epidemiologic cutoff values",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of concern that the clinical breakpoints that have been used in the past may not detect mutational resistance in different species, an extensive effort has been undertaken to establish MICs that are to be expected in wild-type strains that have not been exposed to antifungal agents and that have not acquired resistance mutations. For each species and each antifungal agent, a so-called epidemiologic cutoff value that differentiates the wild-type susceptible strain from those with resistance mutations has been established [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29018/abstract/4,26,29,32-34\">",
"     4,26,29,32-34",
"    </a>",
"    ]. Epidemiologic cutoff values are the most sensitive measure of the emergence of strains with decreased susceptibility to a given agent [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29018/abstract/30,32-38\">",
"     30,32-38",
"    </a>",
"    ], and can be used as a means of tracking the emergence of reduced susceptibility to antifungal agents in surveillance studies [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29018/abstract/30,35,36\">",
"     30,35,36",
"    </a>",
"    ]. Epidemiologic cutoff values can also be used to identify isolates that are less likely to respond to therapy when clinical breakpoints cannot be established because of the rarity of infection with unusual species of fungi [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29018/abstract/26,27,30-32,35,36,39\">",
"     26,27,30-32,35,36,39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR TESTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several situations in which antifungal susceptibility testing should be considered or obtained (",
"    <a class=\"graphic graphic_table graphicRef52140 \" href=\"UTD.htm?41/59/42941\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      C. glabrata isolated from blood or deep sites (eg, normally sterile fluids, tissues, abscesses) should be tested for susceptibility to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      , and an echinocandin",
"     </li>",
"     <li>",
"      Mucosal candidiasis that is unresponsive to usual antifungal therapy",
"     </li>",
"     <li>",
"      Invasive disease that is unresponsive to the initial antifungal regimen",
"     </li>",
"     <li>",
"      Clinical failure in patients with invasive disease caused by species with significant rates of acquired resistance (see",
"      <a class=\"local\" href=\"#H32\">",
"       'Cross-resistance'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Invasive disease caused by unusual fungal species for which antifungal susceptibility patterns have not been well established or are unpredictable",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For species, such as C. krusei, that have high rates of intrinsic resistance, antifungal susceptibility testing is",
"    <strong>",
"     not",
"    </strong>",
"    necessary (",
"    <a class=\"graphic graphic_table graphicRef52140 \" href=\"UTD.htm?41/59/42941\">",
"     table 1",
"    </a>",
"    ). Rather, patients should be treated empirically with antifungal agents known to have activity against the species causing the infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     STANDARDIZED METHODS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antifungal susceptibility testing methods for yeasts are comparable to those used for bacteria [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29018/abstract/3,20,28\">",
"     3,20,28",
"    </a>",
"    ]. The Clinical and Laboratory Standards Institute (CLSI) has developed and published approved methods for both broth dilution testing [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29018/abstract/5,6\">",
"     5,6",
"    </a>",
"    ] and disk diffusion testing of yeasts [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29018/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. These methods are reproducible, accurate, and available for use in clinical laboratories [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29018/abstract/12,27,31,40\">",
"     12,27,31,40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Standardized methods have also been developed for broth dilution testing [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29018/abstract/7\">",
"     7",
"    </a>",
"    ] and disk diffusion testing of filamentous fungi [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29018/abstract/10\">",
"     10",
"    </a>",
"    ], but require further study to establish the in vivo correlation with in vitro data [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29018/abstract/41-44\">",
"     41-44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Broth dilution methods",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the broth macrodilution method, small tubes containing 1 to 2 mL of broth are inoculated with a concentrated antifungal solution and serial two-fold dilutions up to eight dilutions. All tubes are then inoculated with a specified amount of the fungal suspension of interest, suspended in an equal volume, and incubated at a given temperature and length of time. The tubes are then examined for turbidity, which represents fungal growth.",
"   </p>",
"   <p>",
"    The broth microdilution method is a modification of the broth macrodilution test and allows for multiple tests to be performed simultaneously in smaller volumes in a 96-well plate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Yeasts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both broth macrodilution and microdilution methods for in vitro susceptibility testing of yeasts have been established by the CLSI [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29018/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The microdilution method employs a 24 hour incubation at 35&deg;C and an MIC endpoint of &ge;50 percent inhibition (100 percent inhibition for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    ) relative to the control well that has no antifungal agent added (",
"    <a class=\"graphic graphic_picture graphicRef58379 \" href=\"UTD.htm?3/16/3337\">",
"     picture 1",
"    </a>",
"    ). This standardized method provides reliable and reproducible MIC results with good separation of the MIC distribution between wild-type Candida isolates that are susceptible and isolates possessing acquired resistance mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29018/abstract/45-49\">",
"     45-49",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Minimum inhibitory concentration'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The MIC clinical breakpoints for systemically active antifungal agents have been developed in accordance with a \"blueprint\" used for all types of antimicrobial testing [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29018/abstract/27,30,31,50,51\">",
"     27,30,31,50,51",
"    </a>",
"    ]. This blueprint takes into account data that relate the MICs of the specific agent to known resistance mechanisms, the MIC distribution profiles, consideration of cross-resistance patterns, pharmacokinetic (PK) and pharmacodynamic (PD) parameters, and the relationship between in vitro activity (ie, MIC) and clinical outcome according to individual species, as determined by the available clinical efficacy studies [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29018/abstract/12,27,31\">",
"     12,27,31",
"    </a>",
"    ]. MIC breakpoints have been developed for six antifungal agents for the following Candida spp: C. albicans, C. glabrata, C. parapsillosis, C. tropicalis, C. krusei, and C. guilliermondii (",
"    <a class=\"graphic graphic_table graphicRef82995 \" href=\"UTD.htm?25/10/25774\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In 2010 and 2011, the CLSI Subcommittee on Antifungal Susceptibility Testing established new Candida species-specific clinical breakpoints for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29018/abstract/30\">",
"     30",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29018/abstract/31\">",
"     31",
"    </a>",
"    ], and the echinocandins [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29018/abstract/27\">",
"     27",
"    </a>",
"    ]. This change was made due to the recognition that MICs for the various agents were significantly lower for some species than others and that the previous clinical breakpoints for susceptibility of &lt;8",
"    <span class=\"nowrap\">",
"     mcg/ml",
"    </span>",
"    for fluconazole, &lt;1",
"    <span class=\"nowrap\">",
"     mcg/ml",
"    </span>",
"    for voriconazole and &lt;2",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    for the echinocandins were not appropriate for all species.",
"   </p>",
"   <p>",
"    The updated clinical breakpoints are shown in the Table (",
"    <a class=\"graphic graphic_table graphicRef82995 \" href=\"UTD.htm?25/10/25774\">",
"     table 2",
"    </a>",
"    ); the general patterns are as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      , the clinical breakpoints for susceptible (S), susceptible dose-dependent (SDD), and resistant (R), respectively, are the same values for C. albicans, C. tropicalis, and C. parapsilosis, and much higher for C. glabrata, reflecting the need to use higher doses (12",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day) of fluconazole if this agent is used in the management of C. glabrata infection [",
"      <a class=\"abstract\" href=\"UTD.htm?28/21/29018/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      For",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      , the clinical breakpoints are the same values for C. albicans, C. parapsilosis, and C. tropicalis, and are slightly higher for C. krusei. Given the low clinical response of cases of invasive candidiasis due to C. glabrata to voriconazole and the lack of any correlation between clinical response and MIC, the CLSI Subcommittee for Antifungal Testing has not set a clinical breakpoint for C. glabrata [",
"      <a class=\"abstract\" href=\"UTD.htm?28/21/29018/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      For",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/51/20276?source=see_link\">",
"       anidulafungin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/15/10486?source=see_link\">",
"       caspofungin",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/31/44532?source=see_link\">",
"       micafungin",
"      </a>",
"      , the clinical breakpoints are similar for C. albicans, C. tropicalis, and C. krusei, and are higher for C. parapsilosis and C. guilliermondii.",
"     </li>",
"     <li>",
"      For C. glabrata, the clinical breakpoints vary for each echinocandin.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These clinical breakpoints are only applicable to the species listed above due to the lack of outcomes data for the less common species.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Filamentous fungi",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antifungal susceptibility testing may be useful in guiding the selection of antifungal agents for the treatment of invasive disease [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29018/abstract/52-54\">",
"     52-54",
"    </a>",
"    ]. This is especially true for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/60/33737?source=see_link\">",
"     posaconazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    , and the echinocandins, all of which have varying degrees of activity against opportunistic molds [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29018/abstract/43,52-57\">",
"     43,52-57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Using the broth microdilution method for yeasts as a template [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29018/abstract/5\">",
"     5",
"    </a>",
"    ], the CLSI Subcommittee on Antifungal Susceptibility Testing developed a standardized method for filamentous fungi [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29018/abstract/7\">",
"     7",
"    </a>",
"    ]. This method is applicable for testing most rapidly growing molds, including Aspergillus spp, Fusarium spp, Paecilomyces spp, Scedosporium spp, Trichoderma spp, several dematiaceous (brown-black) molds, and the Mucorales [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29018/abstract/7,32,42,43\">",
"     7,32,42,43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The MIC endpoint criterion for molds is the lowest drug concentration that shows complete growth inhibition when testing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/60/33737?source=see_link\">",
"     posaconazole",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29018/abstract/7,43\">",
"     7,43",
"    </a>",
"    ]. Several multicenter studies have documented the reproducibility of this method [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29018/abstract/41-43,58\">",
"     41-43,58",
"    </a>",
"    ] and have shown promise in predicting antifungal efficacy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29018/abstract/59,60\">",
"     59,60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One area of concern has been the difficulty in standardizing this method for determining the in vitro susceptibility of Aspergillus spp to the echinocandins [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29018/abstract/45,61\">",
"     45,61",
"    </a>",
"    ]. It is generally agreed that the proper antifungal endpoint for the echinocandins when testing Aspergillus spp and other molds is the minimum effective concentration (MEC) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29018/abstract/45\">",
"     45",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Minimum effective concentration'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In a comparative study, the use of the MEC endpoint criteria resulted in excellent agreement among 14 of 17 participating laboratories when a panel of 20 isolates of Aspergillus spp was tested against",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/15/10486?source=see_link\">",
"     caspofungin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29018/abstract/45\">",
"     45",
"    </a>",
"    ]. Thus, for echinocandin testing with Aspergillus spp, the MEC offers an endpoint that can give generally reproducible results. However, the finding of aberrant results in 3 of the 17 laboratories suggests a need for caution and further refinement of the echinocandin test method for Aspergillus spp and other filamentous fungi [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29018/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Interpretive breakpoints based on the correlation of in vitro data with clinical outcome have not been established for any mold-drug combination [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29018/abstract/28,62-65\">",
"     28,62-65",
"    </a>",
"    ]. Clinical failure with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    has been associated with MICs of &gt;1",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    for Aspergillus fumigatus, A. terreus, Fusarium spp, and Scedosporium prolificans [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29018/abstract/58,60,62\">",
"     58,60,62",
"    </a>",
"    ]. Clinical failures of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    in the treatment of aspergillosis have been associated with MICs of &gt;8",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29018/abstract/57,62\">",
"     57,62",
"    </a>",
"    ]. Studies of resistance mechanisms in A. fumigatus have shown that MIC cut-offs of &le;1",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    for itraconazole and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    and &le;0.25",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/60/33737?source=see_link\">",
"     posaconazole",
"    </a>",
"    provided separation of the susceptible population from strains with resistance mutations of the CYP51A gene [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29018/abstract/57\">",
"     57",
"    </a>",
"    ]. This is clinically relevant because certain mutations of the CYP51A gene result in predictable patterns of cross-resistance among the azoles. (See",
"    <a class=\"local\" href=\"#H32\">",
"     'Cross-resistance'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Disk diffusion methods",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Yeasts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Agar disk diffusion testing has been used for many years as a simple, flexible, and cost-effective alternative to broth dilution testing of antibacterial agents [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29018/abstract/66,67\">",
"     66,67",
"    </a>",
"    ]. This method has also been incorporated into the CLSI-approved guidelines for antifungal susceptibility testing of yeasts [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29018/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. Zone diameter reference ranges have been defined for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/60/33737?source=see_link\">",
"     posaconazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/31/44532?source=see_link\">",
"     micafungin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/15/10486?source=see_link\">",
"     caspofungin",
"    </a>",
"    when tested against Candida spp [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29018/abstract/27,30,31,68-71\">",
"     27,30,31,68-71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Following 24 hours of incubation at 35&ordm;C, the zone diameters surrounding disks are measured to the nearest millimeter at the point at which there is a prominent reduction in growth (",
"    <a class=\"graphic graphic_picture graphicRef50544 \" href=\"UTD.htm?39/50/40736\">",
"     picture 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The 24 hour zone diameters correlate well with both 24 and 48 hour reference MICs and have allowed the establishment of interpretive breakpoints for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/31/44532?source=see_link\">",
"     micafungin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/15/10486?source=see_link\">",
"     caspofungin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29018/abstract/12,27,29,31,71\">",
"     12,27,29,31,71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although not standardized for testing of yeasts other than Candida, the same disk test method has also been shown to be a useful approach for determining the susceptibility of Cryptococcus neoformans and other non-candidal yeasts to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29018/abstract/72-74\">",
"     72-74",
"    </a>",
"    ]. The interpretation of such results remains under investigation [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29018/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Filamentous fungi",
"    </span>",
"    &nbsp;&mdash;&nbsp;The CLSI Subcommittee on Antifungal Susceptibility Testing has proposed guidelines for disk diffusion testing of filamentous fungi against",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/60/33737?source=see_link\">",
"     posaconazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/15/10486?source=see_link\">",
"     caspofungin",
"    </a>",
"    , based upon the results of a multicenter collaborative study [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29018/abstract/10,75\">",
"     10,75",
"    </a>",
"    ]. The clinical relevance of testing the filamentous fungi remains uncertain because interpretive breakpoints with proven clinical value have yet to be identified or approved by the CLSI or any other regulatory agency [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29018/abstract/10,75\">",
"     10,75",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     COMMERCIAL MIC METHODS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three commercial products have been approved by the United States Food and Drug Administration (FDA) for testing the susceptibility of clinical isolates of Candida to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    : the Etest (bioMerieux, Marcy l&rsquo;Etoile, France), the Sensititre YeastOne colorimetric plate (TREK Diagnostic Systems, Inc, Cleveland, OH) and the VITEK 2 yeast susceptibility test (bioMerieux). The Sensititre YeastOne system and the Etest are also FDA-approved for testing susceptibility to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/0/32773?source=see_link\">",
"     flucytosine",
"    </a>",
"    . The Sensititre and Vitek 2 systems are also approved for testing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/15/10486?source=see_link\">",
"     caspofungin",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Etest",
"    </span>",
"    &nbsp;&mdash;&nbsp;Etest is the most sensitive and reliable method for detecting decreased susceptibility to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    among isolates of Candida spp and Cryptococcus neoformans [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29018/abstract/76-78\">",
"     76-78",
"    </a>",
"    ]. Etest can be used for testing filamentous fungi, such as Aspergillus spp and the Mucorales [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29018/abstract/44,58\">",
"     44,58",
"    </a>",
"    ]; however, it is not FDA-approved for this purpose.",
"   </p>",
"   <p>",
"    The Etest method is based upon the establishment of a stable concentration gradient of an antimicrobial agent following diffusion from a plastic strip into an agar medium. When an Etest strip is placed upon an agar plate that has been inoculated with a test organism and incubated for 24 to 48 hours, an ellipse of growth inhibition occurs, and the intersection of the ellipse with the numeric scale on the strip provides an indication of the MIC (",
"    <a class=\"graphic graphic_picture graphicRef66713 \" href=\"UTD.htm?1/34/1574\">",
"     picture 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The Etest method is applicable to antifungal susceptibility testing of both yeasts and molds. Numerous studies demonstrate the usefulness of Etest for determining the in vitro activity of a variety of antifungal agents including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/0/32773?source=see_link\">",
"     flucytosine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33312?source=see_link\">",
"     ketoconazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/60/33737?source=see_link\">",
"     posaconazole",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/15/10486?source=see_link\">",
"     caspofungin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29018/abstract/44,58,76,78-83\">",
"     44,58,76,78-83",
"    </a>",
"    ]. MICs determined by Etest generally agree well with those determined by the broth dilution reference method; however, this agreement may vary depending upon the antifungal agent tested, the choice of agar medium, and the fungal species [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29018/abstract/84\">",
"     84",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Sensititre YeastOne panel",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Sensititre YeastOne panel is available in a dry-form, 96-well tray with a colorimetric growth indicator. It has excellent accuracy and reproducibility and has been used widely in the United States and elsewhere for testing of Candida and Cryptococcus neoformans [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29018/abstract/40,85\">",
"     40,85",
"    </a>",
"    ]. Following the addition of a broth inoculum suspension and 24 hour incubation, colorimetric MIC results are read at the first well showing a color change of red (growth) to purple (growth inhibition) or blue (no growth).",
"   </p>",
"   <p>",
"    In addition to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/0/32773?source=see_link\">",
"     flucytosine",
"    </a>",
"    , the YeastOne panel may include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/60/33737?source=see_link\">",
"     posaconazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/51/20276?source=see_link\">",
"     anidulafungin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/15/10486?source=see_link\">",
"     caspofungin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/31/44532?source=see_link\">",
"     micafungin",
"    </a>",
"    . In a series of multicenter studies, excellent agreement was observed between broth microdilution and YeastOne MIC results for the triazoles (95 percent agreement) and the three echinocandins (100 percent agreement) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29018/abstract/86,87\">",
"     86,87",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to providing highly reproducible MIC results that reliably predict the MICs determined by the reference broth microdilution method, the YeastOne system provides results for all classes of antifungal agents (polyenes,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/0/32773?source=see_link\">",
"     flucytosine",
"    </a>",
"    , triazoles, and echinocandins) within 24 hours.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     VITEK 2 Yeast Susceptibility Test",
"    </span>",
"    &nbsp;&mdash;&nbsp;The spectrophotometric approach to antifungal susceptibility testing has been shown to be valid and feasible for use in the clinical laboratory [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29018/abstract/88,89\">",
"     88,89",
"    </a>",
"    ] and is an integral component of the European Committee on Antibiotic Susceptibility Testing (EUCAST) method [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29018/abstract/88-90\">",
"     88-90",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The VITEK 2 yeast susceptibility system, which determines growth spectrophotometrically, is the first commercially available automated approach to antifungal susceptibility testing and provides optimal test standardization. It performs fully automated antifungal susceptibility testing of Candida spp against seven antifungal agents (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/60/33737?source=see_link\">",
"     posaconazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/15/10486?source=see_link\">",
"     caspofungin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/31/44532?source=see_link\">",
"     micafungin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/0/32773?source=see_link\">",
"     flucytosine",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29018/abstract/91-94\">",
"     91-94",
"    </a>",
"    ]. This system allows clinical laboratories to perform yeast identification and susceptibility testing simultaneously [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29018/abstract/93\">",
"     93",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Multicenter evaluations have shown agreement of greater than 95 percent in comparisons of the VITEK 2 yeast susceptibility system MICs with reference broth microdilution MICs for the seven antifungal agents used [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29018/abstract/91,92,94\">",
"     91,92,94",
"    </a>",
"    ]. The VITEK 2 system is rapid, with a mean time to results of 12 to 15 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29018/abstract/91,92,94\">",
"     91,92,94",
"    </a>",
"    ]. The availability of rapid quantitative antifungal susceptibility results will be a major step in optimizing the treatment of invasive candidal infections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     FUNGICIDAL ACTIVITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In certain clinical situations, the ability of the antimicrobial agent to kill the pathogen may be important [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29018/abstract/95,96\">",
"     95,96",
"    </a>",
"    ]. These situations involve infection of a site not easily accessed by host defenses",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    of a structure with essential anatomic or physiologic function, such as the heart, central nervous system or bone. In addition, infections in immunocompromised hosts, especially those who are neutropenic, are often thought to require microbicidal therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29018/abstract/95,96\">",
"     95,96",
"    </a>",
"    ]. Furthermore, a microbicidal regimen may prevent the development of resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29018/abstract/97\">",
"     97",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These issues have given rise to a perceived need to assess the fungicidal activity of both new and established antifungal agents against opportunistic pathogens [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29018/abstract/96,98\">",
"     96,98",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    By rigorously following a common procedure, various laboratories may reliably perform and interpret both time-kill and minimum fungicidal concentration determinations with Candida and Aspergillus spp [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29018/abstract/96\">",
"     96",
"    </a>",
"    ]. In standardizing in vitro fungicidal tests, considerable effort must be undertaken to ensure that agents classified as fungicidal by in vitro methods do in fact clear involved organs of the infecting organism in animal models of infection. Even if all of these requirements are met, there is no assurance that such in vitro testing will be meaningful clinically.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUSCEPTIBILITY PATTERNS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many fungal species have predictable antifungal susceptibility patterns. However, rising rates of resistance to antifungal agents have occurred among some fungal species due to the increase in the immunocompromised population, and the frequent use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    and the echinocandins. General patterns of antifungal susceptibility of Candida species are shown in the table (",
"    <a class=\"graphic graphic_table graphicRef61023 \" href=\"UTD.htm?37/33/38428\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Candida spp",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Amphotericin B",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among the various species of Candida, C. albicans remains the most susceptible to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    . The minimum inhibitory concentration (MIC) that encompasses 90 percent of isolates tested (MIC90) is 0.5",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    (",
"    <a class=\"graphic graphic_table graphicRef61023 \" href=\"UTD.htm?37/33/38428\">",
"     table 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef51523 \" href=\"UTD.htm?35/44/36559\">",
"     table 4",
"    </a>",
"    ). Although interpretive breakpoints for amphotericin B have not been established, isolates of Candida for which MICs are &gt;2",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    are unusual and possibly resistant or, at the very least, may require high doses of amphotericin B for optimal treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29018/abstract/38,99\">",
"     38,99",
"    </a>",
"    ]. Both C. glabrata and C. krusei exhibit decreased susceptibility to amphotericin B compared with C. albicans (",
"    <a class=\"graphic graphic_table graphicRef51523 \" href=\"UTD.htm?35/44/36559\">",
"     table 4",
"    </a>",
"    ). C. lusitaniae generally appears susceptible to amphotericin B upon initial isolation from blood, but resistance frequently develops during treatment (",
"    <a class=\"graphic graphic_table graphicRef51523 \" href=\"UTD.htm?35/44/36559\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29018/abstract/100\">",
"     100",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Azoles",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     Fluconazole",
"    </a>",
"    MICs are usually &le;2",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    for C. albicans, C. parapsilosis, C. tropicalis, and C. lusitaniae (",
"    <a class=\"graphic graphic_table graphicRef61023 \" href=\"UTD.htm?37/33/38428\">",
"     table 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef51523 \" href=\"UTD.htm?35/44/36559\">",
"     table 4",
"    </a>",
"    ). Reduced susceptibility to fluconazole is common among isolates of C. glabrata and C. guilliermondii. C. krusei is considered to be intrinsically resistant to fluconazole,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/60/33737?source=see_link\">",
"     posaconazole",
"    </a>",
"    have significantly greater potency than fluconazole against Candida spp, including some species, such as C. krusei and C. guilliermondii, that have reduced susceptibility to fluconazole [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29018/abstract/100-102\">",
"     100-102",
"    </a>",
"    ]. MIC90 values are generally &lt;1",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    for these agents for all species of Candida, with the exception of C. glabrata (",
"    <a class=\"graphic graphic_table graphicRef51523 \" href=\"UTD.htm?35/44/36559\">",
"     table 4",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Echinocandins",
"    </span>",
"    &nbsp;&mdash;&nbsp;All three of the echinocandins exhibit excellent potency against Candida spp (",
"    <a class=\"graphic graphic_table graphicRef61023 \" href=\"UTD.htm?37/33/38428\">",
"     table 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef51523 \" href=\"UTD.htm?35/44/36559\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29018/abstract/103\">",
"     103",
"    </a>",
"    ]. C. albicans, C. glabrata, and C. tropicalis are highly susceptible to all three agents, whereas elevated MICs are seen for C. parapsilosis and C. guilliermondii. Acquired resistance to the echinocandins remains sporadic [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29018/abstract/4,104\">",
"     4,104",
"    </a>",
"    ], but has been documented for individual cases of infection with C. albicans, C. glabrata, C. lusitaniae, C. tropicalis, and C. parapsilosis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29018/abstract/105-111\">",
"     105-111",
"    </a>",
"    ]. There is increasing concern that some C. glabrata bloodstream isolates with resistance to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    are also resistant to the echinocandins [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29018/abstract/112\">",
"     112",
"    </a>",
"    ]. This is a serious concern and argues for continued surveillance for resistance using standardized antifungal susceptibility testing. (See",
"    <a class=\"local\" href=\"#H35\">",
"     'Echinocandins'",
"    </a>",
"    below.)",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Flucytosine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/0/32773?source=see_link\">",
"     Flucytosine",
"    </a>",
"    is generally quite active against most species of Candida with 95 percent of clinical isolates tested being susceptible with an MIC of &le;4",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29018/abstract/113\">",
"     113",
"    </a>",
"    ]. Flucytosine MICs are generally very low for C. albicans, C. glabrata, C. parapsilosis, C. tropicalis, C. guilliermondii, and C. lusitaniae (",
"    <a class=\"graphic graphic_table graphicRef61023 \" href=\"UTD.htm?37/33/38428\">",
"     table 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef51523 \" href=\"UTD.htm?35/44/36559\">",
"     table 4",
"    </a>",
"    ). In contrast, resistance to flucytosine is common among isolates of C. krusei.",
"   </p>",
"   <p>",
"    The choice of antifungal regimen for infections caused by each of the Candida species described above is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/13/29914?source=see_link\">",
"     \"Treatment of candidemia and invasive candidiasis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Other yeasts",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to Candida spp, the non-candidal yeasts comprise a very diverse collection of opportunistic pathogens [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29018/abstract/74,102\">",
"     74,102",
"    </a>",
"    ] It is important to understand that Cryptococcus, Trichosporon, Rhodotorula, and Blastoschizomyces spp are intrinsically resistant to the echinocandin class of agents [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29018/abstract/114\">",
"     114",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     Amphotericin B",
"    </a>",
"    is generally active against these organisms with the notable exception of Trichosporon asahii, which should be considered resistant to amphotericin B (",
"    <a class=\"graphic graphic_table graphicRef71985 \" href=\"UTD.htm?29/2/29742\">",
"     table 5",
"    </a>",
"    ). MICs for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/0/32773?source=see_link\">",
"     flucytosine",
"    </a>",
"    are generally &lt;1",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    for isolates of Rhodotorula and Saccharomyces spp but are &gt;4",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    for C. neoformans, and B. capitatus.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     Fluconazole",
"    </a>",
"    MICs are moderately elevated (MIC90 = 8",
"    <span class=\"nowrap\">",
"     mcg/mL)",
"    </span>",
"    for isolates of C. neoformans, Trichosporon spp, Saccharomyces spp, and B. capitatus [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29018/abstract/115-124\">",
"     115-124",
"    </a>",
"    ]&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef71985 \" href=\"UTD.htm?29/2/29742\">",
"     table 5",
"    </a>",
"    ). Aside from Rhodotorula spp, which are resistant to all azoles,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/60/33737?source=see_link\">",
"     posaconazole",
"    </a>",
"    are very active against the non-candidal yeasts (",
"    <a class=\"graphic graphic_table graphicRef71985 \" href=\"UTD.htm?29/2/29742\">",
"     table 5",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Molds",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     Amphotericin B",
"    </a>",
"    is generally active against Aspergillus spp (",
"    <a class=\"graphic graphic_table graphicRef82439 \" href=\"UTD.htm?29/34/30254\">",
"     table 6",
"    </a>",
"    ); however, A. terreus is considered to be resistant to amphotericin B [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29018/abstract/125\">",
"     125",
"    </a>",
"    ]. MICs for amphotericin B are low for the Mucorales, whereas Fusarium spp S. apiospermum and S. prolificans are considered resistant to this agent (",
"    <a class=\"graphic graphic_table graphicRef82439 \" href=\"UTD.htm?29/34/30254\">",
"     table 6",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    All of the triazoles have potent activity against Aspergillus spp. [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29018/abstract/55,126\">",
"     55,126",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     Voriconazole",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/60/33737?source=see_link\">",
"     posaconazole",
"    </a>",
"    generally are more active than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    against Fusarium and S. prolificans [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29018/abstract/55,126,127\">",
"     55,126,127",
"    </a>",
"    ]. Both posaconazole and voriconazole are active against S. apiospermum, whereas only posaconazole shows activity against the Mucorales.",
"   </p>",
"   <p>",
"    The MEC for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/15/10486?source=see_link\">",
"     caspofungin",
"    </a>",
"    and the other echinocandins is usually quite low for Aspergillus spp, but is elevated for the non-Aspergillus molds (",
"    <a class=\"graphic graphic_table graphicRef82439 \" href=\"UTD.htm?29/34/30254\">",
"     table 6",
"    </a>",
"    ). The echinocandins are not recommended as first-line therapy for infections caused by Aspergillus spp since their efficacy for this indication has not been established. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/18/28970?source=see_link\">",
"     \"Treatment and prevention of invasive aspergillosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     CROSS-RESISTANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because the azole class of antifungal agents shares a common mechanism of action and (in most cases) of resistance, there is concern regarding the development of cross-resistance among the azoles with both Candida and Aspergillus spp [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29018/abstract/11,57,128,129\">",
"     11,57,128,129",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Candida spp",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h3\">",
"     Azoles",
"    </span>",
"    &nbsp;&mdash;&nbsp;The potential for cross-resistance among the available triazoles is evident, especially among Candida spp capable of overexpression of Candida Drug Resistance (CDR) efflux pumps (eg, C. glabrata), and to a lesser extent those with overexpression of",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    mutation in the target enzyme, lanosterol 14-alpha-demethylase [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29018/abstract/128,130,131\">",
"     128,130,131",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among Candida isolates, there is a strong positive correlation between",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    MICs and those of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/60/33737?source=see_link\">",
"     posaconazole",
"    </a>",
"    , indicating considerable cross-resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29018/abstract/128,132\">",
"     128,132",
"    </a>",
"    ]. Thus, resistance to fluconazole may serve as a surrogate marker in predicting resistance to the other extended-spectrum triazoles with Candida spp. An analysis of cross-resistance among fluconazole and the other triazoles demonstrated that isolates of Candida spp for which fluconazole MICs are &ge;64",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    (resistant) also tend to be less susceptible to itraconazole [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29018/abstract/128,133\">",
"     128,133",
"    </a>",
"    ], voriconazole [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29018/abstract/73,128\">",
"     73,128",
"    </a>",
"    ], and posaconazole [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29018/abstract/128,132\">",
"     128,132",
"    </a>",
"    ]. Fluconazole MICs of &le;32",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    predict susceptibility, and MICs of &ge;64",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    predict resistance of Candida spp to voriconazole and posaconazole [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29018/abstract/128,132\">",
"     128,132",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Certain Candida species have predictable patterns of cross-resistance. Notably, none of the triazoles exhibit meaningful activity against",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    -resistant isolates of C. glabrata, whereas",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/60/33737?source=see_link\">",
"     posaconazole",
"    </a>",
"    are active against the intrinsically fluconazole-resistant C. krusei [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29018/abstract/128\">",
"     128",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Evidence supporting the clinical relevance of azole cross-resistance has been documented in case reports and case series of invasive candidiasis in which clinically significant microbial resistance to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    has been reported among critically ill patients and immunocompromised patients with a history of substantial recent azole exposure, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    , before voriconazole is given [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29018/abstract/128,129\">",
"     128,129",
"    </a>",
"    ]. These concerns have led some experts to suggest fluconazole susceptibility testing of initial blood isolates of Candida as a means of identifying those patients who may not respond optimally to either voriconazole or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/60/33737?source=see_link\">",
"     posaconazole",
"    </a>",
"    therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29018/abstract/15,17,129\">",
"     15,17,129",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <br/>",
"    There is increasing concern that some C. glabrata bloodstream isolates with resistance to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    are also resistant to the echinocandins [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29018/abstract/112\">",
"     112",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H35\">",
"     'Echinocandins'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h3\">",
"     Echinocandins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cross-resistance among echinocandins has been documented and is usually related to mutations in the FKS1 (glucan synthase) gene [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29018/abstract/46,47,134\">",
"     46,47,134",
"    </a>",
"    ]. A 16- to 128-fold change in MIC relative to the MIC of a fully susceptible wild-type strain is consistently observed for all three echinocandins when tested against a Candida strain with FKS1 mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29018/abstract/134\">",
"     134",
"    </a>",
"    ]. The MICs for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/15/10486?source=see_link\">",
"     caspofungin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/31/44532?source=see_link\">",
"     micafungin",
"    </a>",
"    tend to be somewhat higher than those determined for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/51/20276?source=see_link\">",
"     anidulafungin",
"    </a>",
"    in such strains [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29018/abstract/134\">",
"     134",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical significance of such differences remains to be determined; however, the more conservative approach would be to consider those isolates shown to be resistant to one of the echinocandins to be resistant to the other agents in the class.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/15/10486?source=see_link\">",
"     Caspofungin",
"    </a>",
"    results predict those of either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/51/20276?source=see_link\">",
"     anidulafungin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/31/44532?source=see_link\">",
"     micafungin",
"    </a>",
"    with an agreement of &gt;98 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29018/abstract/27\">",
"     27",
"    </a>",
"    ]. Thus, the susceptibility results for caspofungin may be considered to be predictive of those for the other two agents in the class.",
"   </p>",
"   <p>",
"    There is increasing concern that some C. glabrata bloodstream isolates with resistance to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    are also resistant to the echinocandins. Such resistance is termed co-resistance (rather than cross-resistance) because the resistance to the echinocandins involves a different mechanism than the resistance to the azoles. In a surveillance study of the in vitro susceptibility of 1669 C. glabrata bloodstream isolates collected in the United States between 2006 and 2010, 162 isolates (9.7 percent) were resistant to fluconazole, of which 98.8 percent were also not susceptible to voriconazole (MIC &gt;0.5",
"    <span class=\"nowrap\">",
"     mcg/mL),",
"    </span>",
"    and 9.3, 9.3, and 8.0 percent were resistant to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/51/20276?source=see_link\">",
"     anidulafungin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/15/10486?source=see_link\">",
"     caspofungin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/31/44532?source=see_link\">",
"     micafungin",
"    </a>",
"    , respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29018/abstract/112\">",
"     112",
"    </a>",
"    ]. Of the 162 isolates that were resistant to fluconazole, 18 (11.1 percent) were resistant to one or more of the echinocandins; all of these isolates contained an FKS1 or FKS2 mutation. In comparison, there were no echinocandin-resistant strains detected among 110 fluconazole-resistant C. glabrata isolates tested between 2001 and 2004, years during which only one echinocandin, caspofungin, was available and echinocandins were used sparingly. At this point, it is not clear what impact these findings will have on treatment regimens for candidemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Filamentous fungi",
"    </span>",
"    &nbsp;&mdash;&nbsp;Investigation of azole cross-resistance among filamentous fungi has focused on studies of Aspergillus fumigatus [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29018/abstract/57,128,135\">",
"     57,128,135",
"    </a>",
"    ]. Cross-resistance among the triazoles is dependent upon specific mutations in the A. fumigatus CYP51A gene [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29018/abstract/57\">",
"     57",
"    </a>",
"    ]. Certain mutations result in cross-resistance between",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/60/33737?source=see_link\">",
"     posaconazole",
"    </a>",
"    but not",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    , and vice versa [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29018/abstract/57\">",
"     57",
"    </a>",
"    ]. Other mutations result in resistance to all four triazoles [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29018/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Given the lack of complete cross-resistance among the azoles for Aspergillus spp, antifungal susceptibility testing is warranted to identify resistant phenotypes in patients with invasive disease who have clinical failure of initial therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/21/29018/abstract/57\">",
"     57",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Indications for testing'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The need for reproducible, clinically relevant antifungal susceptibility testing has been prompted by the increasing number of invasive fungal infections, the expanding use of new and established antifungal agents, and recognition of antifungal resistance as an important clinical problem. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The Clinical and Laboratory Standards Institute (CLSI) Subcommittee on Antifungal Susceptibility Testing has generated consensus documents describing standardized methods for broth- and agar-based antifungal susceptibility testing. As a result, in vitro antifungal susceptibility testing plays an increasingly important role in guiding therapeutic decision making, as an aid in drug development studies, and as a means of tracking the development of antifungal resistance in epidemiologic studies. Several commercial methods for antifungal susceptibility testing are available. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Standardized methods'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H17\">",
"       'Commercial MIC methods'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In order to be useful clinically, in vitro susceptibility testing of antimicrobial agents should reliably predict the in vivo response to therapy. The in vitro susceptibility of an infecting organism to the antimicrobial agent is only one of several factors that may influence the likelihood that therapy will be successful. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Clinical relevance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are several situations in which antifungal susceptibility testing should be considered or obtained (",
"      <a class=\"graphic graphic_table graphicRef52140 \" href=\"UTD.htm?41/59/42941\">",
"       table 1",
"      </a>",
"      ):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      C. glabrata isolated from blood or deep sites (eg, normally sterile fluids, tissues, abscesses) should be tested for susceptibility to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      , and an echinocandin",
"     </li>",
"     <li>",
"      Mucosal candidiasis that is unresponsive to usual antifungal therapy",
"     </li>",
"     <li>",
"      Invasive disease that is unresponsive to the initial antifungal regimen",
"     </li>",
"     <li>",
"      Clinical failure in patients with invasive disease caused by species with significant rates of acquired resistance (see",
"      <a class=\"local\" href=\"#H32\">",
"       'Cross-resistance'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Invasive disease caused by unusual fungal species for which antifungal susceptibility patterns have not been well established or are unpredictable",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients infected with species, such as C. krusei, that have high rates of intrinsic resistance, antifungal susceptibility testing is",
"      <strong>",
"       not",
"      </strong>",
"      necessary (",
"      <a class=\"graphic graphic_table graphicRef52140 \" href=\"UTD.htm?41/59/42941\">",
"       table 1",
"      </a>",
"      ). Rather, such patients should be treated empirically with antifungal agents known to have activity against the species causing the infection. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Indications for testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Many fungal species have predictable antifungal susceptibility patterns (",
"      <a class=\"graphic graphic_table graphicRef61023 \" href=\"UTD.htm?37/33/38428\">",
"       table 3",
"      </a>",
"      ). However, rising rates of resistance to antifungal agents have occurred among some fungal species due to the increase in the immunocompromised population and the frequent use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      and echinocandins. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Susceptibility patterns'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cross-resistance is a concern, particularly among the azole antifungal agents. (See",
"      <a class=\"local\" href=\"#H32\">",
"       'Cross-resistance'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29018/abstract/1\">",
"      Johnson EM. Issues in antifungal susceptibility testing. J Antimicrob Chemother 2008; 61 Suppl 1:i13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29018/abstract/2\">",
"      Pfaller MA. New developments in the antifungal susceptibility testing of Candida. Curr Fungal Infect Reports 2008; 2:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29018/abstract/3\">",
"      Rex JH, Pfaller MA. Has antifungal susceptibility testing come of age? Clin Infect Dis 2002; 35:982.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29018/abstract/4\">",
"      Pfaller MA. Antifungal drug resistance: mechanisms, epidemiology, and consequences for treatment. Am J Med 2012; 125:S3.",
"     </a>",
"    </li>",
"    <li>",
"     Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of yeasts; Approved standard, 3rd ed, CLSI document M27-A3, Clinical and Laboratory Standards Institute, Wayne, PA 2008.",
"    </li>",
"    <li>",
"     Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of yeasts; Informational supplement, 3rd ed, CLSI document M27-S3, Clinical and Laboratory Standards Institute, Wayne, PA 2008.",
"    </li>",
"    <li>",
"     Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi; Approved standard, 2nd ed, CLSI document M38-A2, Clinical and Laboratory Standards Institute, Wayne, PA 2008.",
"    </li>",
"    <li>",
"     Clinical and Laboratory Standards Institute. Method for antifungal disk diffusion susceptibility testing of yeasts; Approved guideline. CLSI document M44-A, Clinical and Laboratory Standards Institute, Wayne, PA 2004.",
"    </li>",
"    <li>",
"     Clinical and Laboratory Standards Institute. Zone diameter interpretive standards, corresponding minimal inhibitory concentration (MIC) interpretive breakpoints, and quality control limits for antifungal disk diffusion susceptibility testing of yeasts; Informational supplement, 2nd ed, CLSI document M44-S2, Clinical and Laboratory Standards Institute, Wayne, PA 2008.",
"    </li>",
"    <li>",
"     Clinical and Laboratory Standards Institute. Method for antifungal disk diffusion susceptibility testing of filamentous fungi; Proposed guideline. CLSI document M51-P, Clinical and Laboratory Standards Institute, Wayne, PA 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29018/abstract/11\">",
"      Kanafani ZA, Perfect JR. Antimicrobial resistance: resistance to antifungal agents: mechanisms and clinical impact. Clin Infect Dis 2008; 46:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29018/abstract/12\">",
"      Pfaller MA, Diekema DJ, Sheehan DJ. Interpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testing. Clin Microbiol Rev 2006; 19:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29018/abstract/13\">",
"      Rex JH, Pfaller MA, Walsh TJ, et al. Antifungal susceptibility testing: practical aspects and current challenges. Clin Microbiol Rev 2001; 14:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29018/abstract/14\">",
"      Baddley JW, Patel M, Jones M, et al. Utility of real-time antifungal susceptibility testing for fluconazole in the treatment of candidemia. Diagn Microbiol Infect Dis 2004; 50:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29018/abstract/15\">",
"      Collins CD, Eschenauer GA, Salo SL, Newton DW. To test or not to test: a cost minimization analysis of susceptibility testing for patients with documented Candida glabrata fungemias. J Clin Microbiol 2007; 45:1884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29018/abstract/16\">",
"      Hadley S, Martinez JA, McDermott L, et al. Real-time antifungal susceptibility screening aids management of invasive yeast infections in immunocompromised patients. J Antimicrob Chemother 2002; 49:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29018/abstract/17\">",
"      Parkins MD, Sabuda DM, Elsayed S, Laupland KB. Adequacy of empirical antifungal therapy and effect on outcome among patients with invasive Candida species infections. J Antimicrob Chemother 2007; 60:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29018/abstract/18\">",
"      Magill SS, Shields C, Sears CL, et al. Triazole cross-resistance among Candida spp.: case report, occurrence among bloodstream isolates, and implications for antifungal therapy. J Clin Microbiol 2006; 44:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29018/abstract/19\">",
"      Armstrong-James D. Invasive Candida species infection: the importance of adequate empirical antifungal therapy. J Antimicrob Chemother 2007; 60:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29018/abstract/20\">",
"      Forrest G. Role of antifungal susceptibility testing in patient management. Curr Opin Infect Dis 2006; 19:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29018/abstract/21\">",
"      Pfaller MA. Antifungal susceptibility testing methods. Curr Drug Targets 2005; 6:929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29018/abstract/22\">",
"      Pfaller MA, Rex JH, Rinaldi MG. Antifungal susceptibility testing: technical advances and potential clinical applications. Clin Infect Dis 1997; 24:776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29018/abstract/23\">",
"      Arikan S. Current status of antifungal susceptibility testing methods. Med Mycol 2007; 45:569.",
"     </a>",
"    </li>",
"    <li>",
"     Sanders WE Jr, Sanders CC. Do in vitro antimicrobial susceptibility tests accurately predict therapeutic responsiveness in infected patients?. In: Significance of medical microbiology in the care of patients, 2nd ed, Lorian V (Ed), Williams &amp; Wilkins, Baltimore 1982. p.325.",
"    </li>",
"    <li>",
"     Diekema DJ, Pfaller MA. Utility of antifungal suceptibility testing and clinical correlations. In: Interactions of Yeasts, Moulds, and Antifungal Agents: How To Detect Resistance, Hall GS (Ed), Springer, New York 2012. p.131.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29018/abstract/26\">",
"      Turnidge J, Paterson DL. Setting and revising antibacterial susceptibility breakpoints. Clin Microbiol Rev 2007; 20:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29018/abstract/27\">",
"      Pfaller MA, Diekema DJ, Andes D, et al. Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria. Drug Resist Updat 2011; 14:164.",
"     </a>",
"    </li>",
"    <li>",
"     Johnson EM, Espinel-Ingroff AV, Pfaller MA. Susceptibility test methods: yeasts and filamentous fungi. In: Manual of Clinical Microbiology, 10th ed, Versalovic J.  (Ed), ASM Press, Washington, DC 2011. p.2020.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29018/abstract/29\">",
"      Pfaller MA, Diekema DJ. Progress in antifungal susceptibility testing of Candida spp. by use of Clinical and Laboratory Standards Institute broth microdilution methods, 2010 to 2012. J Clin Microbiol 2012; 50:2846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29018/abstract/30\">",
"      Pfaller MA, Andes D, Diekema DJ, et al. Wild-type MIC distributions, epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and Candida: time for harmonization of CLSI and EUCAST broth microdilution methods. Drug Resist Updat 2010; 13:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29018/abstract/31\">",
"      Pfaller MA, Andes D, Arendrup MC, et al. Clinical breakpoints for voriconazole and Candida spp. revisited: review of microbiologic, molecular, pharmacodynamic, and clinical data as they pertain to the development of species-specific interpretive criteria. Diagn Microbiol Infect Dis 2011; 70:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29018/abstract/32\">",
"      Kahlmeter G, Brown DF, Goldstein FW, et al. European harmonization of MIC breakpoints for antimicrobial susceptibility testing of bacteria. J Antimicrob Chemother 2003; 52:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29018/abstract/33\">",
"      Simjee S, Silley P, Werling HO, Bywater R. Potential confusion regarding the term 'resistance' in epidemiological surveys. J Antimicrob Chemother 2008; 61:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29018/abstract/34\">",
"      Turnidge J, Kahlmeter G, Kronvall G. Statistical characterisation of bacterial wild-type MIC value distributions and the determination of epidemiological cut-off values. Clin Microbiol Infect 2006; 12:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29018/abstract/35\">",
"      Pfaller MA, Boyken L, Hollis RJ, et al. Wild-type MIC distributions and epidemiological cutoff values for the echinocandins and Candida spp. J Clin Microbiol 2010; 48:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29018/abstract/36\">",
"      Pfaller MA, Boyken L, Hollis RJ, et al. Wild-type MIC distributions and epidemiological cutoff values for posaconazole and voriconazole and Candida spp. as determined by 24-hour CLSI broth microdilution. J Clin Microbiol 2011; 49:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29018/abstract/37\">",
"      Pfaller MA, Castanheira M, Diekema DJ, et al. Triazole and echinocandin MIC distributions with epidemiological cutoff values for differentiation of wild-type strains from non-wild-type strains of six uncommon species of Candida. J Clin Microbiol 2011; 49:3800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29018/abstract/38\">",
"      Pfaller MA, Espinel-Ingroff A, Canton E, et al. Wild-type MIC distributions and epidemiological cutoff values for amphotericin B, flucytosine, and itraconazole and Candida spp. as determined by CLSI broth microdilution. J Clin Microbiol 2012; 50:2040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29018/abstract/39\">",
"      Pfaller MA, Diekema DJ. Wild-type MIC distributions and epidemiological cutoff values for fluconazole and Candida: time for new clinical breakpoints? Curr Fungal Infect Rep 2010; 4:168. file://www.springerlink.com/content/x783475020457u0p/ (Accessed on February 10, 2012)",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29018/abstract/40\">",
"      Pfaller MA, Jones RN, Microbiology Resource Committee, College of American Pathologists. Performance accuracy of antibacterial and antifungal susceptibility test methods: report from the College of American Pathologists Microbiology Surveys Program (2001-2003). Arch Pathol Lab Med 2006; 130:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29018/abstract/41\">",
"      Espinel-Ingroff A, Dawson K, Pfaller M, et al. Comparative and collaborative evaluation of standardization of antifungal susceptibility testing for filamentous fungi. Antimicrob Agents Chemother 1995; 39:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29018/abstract/42\">",
"      Espinel-Ingroff A, Bartlett M, Bowden R, et al. Multicenter evaluation of proposed standardized procedure for antifungal susceptibility testing of filamentous fungi. J Clin Microbiol 1997; 35:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29018/abstract/43\">",
"      Espinel-Ingroff A, Bartlett M, Chaturvedi V, et al. Optimal susceptibility testing conditions for detection of azole resistance in Aspergillus spp.: NCCLS collaborative evaluation. National Committee for Clinical Laboratory Standards. Antimicrob Agents Chemother 2001; 45:1828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29018/abstract/44\">",
"      Espinel-Ingroff A. Comparison of three commercial assays and a modified disk diffusion assay with two broth microdilution reference assays for testing zygomycetes, Aspergillus spp., Candida spp., and Cryptococcus neoformans with posaconazole and amphotericin B. J Clin Microbiol 2006; 44:3616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29018/abstract/45\">",
"      Odds FC, Motyl M, Andrade R, et al. Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species. J Clin Microbiol 2004; 42:3475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29018/abstract/46\">",
"      Balashov SV, Park S, Perlin DS. Assessing resistance to the echinocandin antifungal drug caspofungin in Candida albicans by profiling mutations in FKS1. Antimicrob Agents Chemother 2006; 50:2058.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29018/abstract/47\">",
"      Park S, Kelly R, Kahn JN, et al. Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates. Antimicrob Agents Chemother 2005; 49:3264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29018/abstract/48\">",
"      Pfaller MA, Castanheira M, Diekema DJ, et al. Comparison of European Committee on Antimicrobial Susceptibility Testing (EUCAST) and Etest methods with the CLSI broth microdilution method for echinocandin susceptibility testing of Candida species. J Clin Microbiol 2010; 48:1592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29018/abstract/49\">",
"      Perlin D. Echinocandin-resistant Candida: molecular methods and phenotypes. Curr Fungal Infect Reports 2011; 5:113.",
"     </a>",
"    </li>",
"    <li>",
"     Clinical and Laboratory Standards Institute. Development of in vitro susceptibility testing interpretive criteria and quality control parameters; Approved guideline, 3rd edition, CLSI document M23-A3, Wayne, PA 2008.",
"    </li>",
"    <li>",
"     Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing: 15th informational supplement. CLSI document M100-S15, Clinical and Laboratory Standards Institute, Wayne, PA 2007.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29018/abstract/52\">",
"      Alastruey-Izquierdo A, Cuenca-Estrella M, Monz&oacute;n A, et al. Antifungal susceptibility profile of clinical Fusarium spp. isolates identified by molecular methods. J Antimicrob Chemother 2008; 61:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29018/abstract/53\">",
"      Alcazar-Fuoli L, Mellado E, Alastruey-Izquierdo A, et al. Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification. Antimicrob Agents Chemother 2008; 52:1244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29018/abstract/54\">",
"      Castelli MV, Alastruey-Izquierdo A, Cuesta I, et al. Susceptibility testing and molecular classification of Paecilomyces spp. Antimicrob Agents Chemother 2008; 52:2926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29018/abstract/55\">",
"      Diekema DJ, Messer SA, Hollis RJ, et al. Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi. J Clin Microbiol 2003; 41:3623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29018/abstract/56\">",
"      Pfaller MA, Messer SA, Boyken L, et al. In vitro survey of triazole cross-resistance among more than 700 clinical isolates of Aspergillus species. J Clin Microbiol 2008; 46:2568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29018/abstract/57\">",
"      Rodriguez-Tudela JL, Alcazar-Fuoli L, Mellado E, et al. Epidemiological cutoffs and cross-resistance to azole drugs in Aspergillus fumigatus. Antimicrob Agents Chemother 2008; 52:2468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29018/abstract/58\">",
"      Espinel-Ingroff A. Evaluation of broth microdilution testing parameters and agar diffusion Etest procedure for testing susceptibilities of Aspergillus spp. to caspofungin acetate (MK-0991). J Clin Microbiol 2003; 41:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29018/abstract/59\">",
"      Odds FC, Van Gerven F, Espinel-Ingroff A, et al. Evaluation of possible correlations between antifungal susceptibilities of filamentous fungi in vitro and antifungal treatment outcomes in animal infection models. Antimicrob Agents Chemother 1998; 42:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29018/abstract/60\">",
"      Lass-Fl&ouml;rl C, Kofler G, Kropshofer G, et al. In-vitro testing of susceptibility to amphotericin B is a reliable predictor of clinical outcome in invasive aspergillosis. J Antimicrob Chemother 1998; 42:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29018/abstract/61\">",
"      Bartizal C, Odds FC. Influences of methodological variables on susceptibility testing of caspofungin against Candida species and Aspergillus fumigatus. Antimicrob Agents Chemother 2003; 47:2100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29018/abstract/62\">",
"      Mosquera J, Denning DW. Azole cross-resistance in Aspergillus fumigatus. Antimicrob Agents Chemother 2002; 46:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29018/abstract/63\">",
"      Espinel-Ingroff A, Diekema DJ, Fothergill A, et al. Wild-type MIC distributions and epidemiological cutoff values for the triazoles and six Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document). J Clin Microbiol 2010; 48:3251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29018/abstract/64\">",
"      Espinel-Ingroff A, Fothergill A, Fuller J, et al. Wild-type MIC distributions and epidemiological cutoff values for caspofungin and Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document). Antimicrob Agents Chemother 2011; 55:2855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29018/abstract/65\">",
"      Espinel-Ingroff A, Cuenca-Estrella M, Fothergill A, et al. Wild-type MIC distributions and epidemiological cutoff values for amphotericin B and Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document). Antimicrob Agents Chemother 2011; 55:5150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29018/abstract/66\">",
"      Jones RN, College of American Pathologists Microbiology Resource Committe. Method preferences and test accuracy of antimicrobial susceptibility testing: updates from the College of Amercian Pathologists Microbiology Surveys Program. Arch Pathol Lab Med 2001; 125:1285.",
"     </a>",
"    </li>",
"    <li>",
"     National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial disk susceptibility tests: Approved standard, 8th ed, NCCLS document M2-A8, National Committee for Clinical Laboratory Standards, Wayne, PA 2003.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29018/abstract/68\">",
"      Barry A, Bille J, Brown S, et al. Quality control limits for fluconazole disk susceptibility tests on Mueller-Hinton agar with glucose and methylene blue. J Clin Microbiol 2003; 41:3410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29018/abstract/69\">",
"      Pfaller MA, Barry A, Bille J, et al. Quality control limits for voriconazole disk susceptibility tests on Mueller-Hinton agar with glucose and methylene blue. J Clin Microbiol 2004; 42:1716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29018/abstract/70\">",
"      Brown S, Traczewski M. Quality control limits for posaconazole disk susceptibility tests on Mueller-Hinton agar with glucose and methylene blue. J Clin Microbiol 2007; 45:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29018/abstract/71\">",
"      Brown SD, Traczewski MM. Caspofungin disk diffusion breakpoints and quality control. J Clin Microbiol 2008; 46:1927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29018/abstract/72\">",
"      Pfaller MA, Diekema DJ, Rinaldi MG, et al. Results from the ARTEMIS DISK Global Antifungal Surveillance Study: a 6.5-year analysis of susceptibilities of Candida and other yeast species to fluconazole and voriconazole by standardized disk diffusion testing. J Clin Microbiol 2005; 43:5848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29018/abstract/73\">",
"      Pfaller MA, Diekema DJ, Gibbs DL, et al. Results from the ARTEMIS DISK Global Antifungal Surveillance study, 1997 to 2005: an 8.5-year analysis of susceptibilities of Candida species and other yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing. J Clin Microbiol 2007; 45:1735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29018/abstract/74\">",
"      Pfaller MA, Diekema DJ, Gibbs DL, et al. Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: 10.5-year analysis of susceptibilities of noncandidal yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing. J Clin Microbiol 2009; 47:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29018/abstract/75\">",
"      Espinel-Ingroff A, Arthington-Skaggs B, Iqbal N, et al. Multicenter evaluation of a new disk agar diffusion method for susceptibility testing of filamentous fungi with voriconazole, posaconazole, itraconazole, amphotericin B, and caspofungin. J Clin Microbiol 2007; 45:1811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29018/abstract/76\">",
"      Wanger A, Mills K, Nelson PW, Rex JH. Comparison of Etest and National Committee for Clinical Laboratory Standards broth macrodilution method for antifungal susceptibility testing: enhanced ability to detect amphotericin B-resistant Candida isolates. Antimicrob Agents Chemother 1995; 39:2520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29018/abstract/77\">",
"      Baker CN, Stocker SA, Culver DH, Thornsberry C. Comparison of the E Test to agar dilution, broth microdilution, and agar diffusion susceptibility testing techniques by using a special challenge set of bacteria. J Clin Microbiol 1991; 29:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29018/abstract/78\">",
"      Lozano-Chiu M, Paetznick VL, Ghannoum MA, Rex JH. Detection of resistance to amphotericin B among Cryptococcus neoformans clinical isolates: performances of three different media assessed by using E-test and National Committee for Clinical Laboratory Standards M27-A methodologies. J Clin Microbiol 1998; 36:2817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29018/abstract/79\">",
"      Clancy CJ, Nguyen MH. Correlation between in vitro susceptibility determined by E test and response to therapy with amphotericin B: results from a multicenter prospective study of candidemia. Antimicrob Agents Chemother 1999; 43:1289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29018/abstract/80\">",
"      Pfaller MA, Boyken L, Messer SA, et al. Evaluation of the etest method using Mueller-Hinton agar with glucose and methylene blue for determining amphotericin B MICs for 4,936 clinical isolates of Candida species. J Clin Microbiol 2004; 42:4977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29018/abstract/81\">",
"      Alexander BD, Byrne TC, Smith KL, et al. Comparative evaluation of Etest and sensititre yeastone panels against the Clinical and Laboratory Standards Institute M27-A2 reference broth microdilution method for testing Candida susceptibility to seven antifungal agents. J Clin Microbiol 2007; 45:698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29018/abstract/82\">",
"      Chryssanthou E, Cuenca-Estrella M. Comparison of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antibiotic Susceptibility Testing proposed standard and the E-test with the NCCLS broth microdilution method for voriconazole and caspofungin susceptibility testing of yeast species. J Clin Microbiol 2002; 40:3841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29018/abstract/83\">",
"      Espinel-Ingroff A, Rezusta A. E-test method for testing susceptibilities of Aspergillus spp. to the new triazoles voriconazole and posaconazole and to established antifungal agents: comparison with NCCLS broth microdilution method. J Clin Microbiol 2002; 40:2101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29018/abstract/84\">",
"      Espinel-Ingroff A, Pfaller M, Erwin ME, Jones RN. Interlaboratory evaluation of Etest method for testing antifungal susceptibilities of pathogenic yeasts to five antifungal agents by using Casitone agar and solidified RPMI 1640 medium with 2% glucose. J Clin Microbiol 1996; 34:848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29018/abstract/85\">",
"      Morace G, Amato G, Bistoni F, et al. Multicenter comparative evaluation of six commercial systems and the national committee for clinical laboratory standards m27-a broth microdilution method for fluconazole susceptibility testing of Candida species. J Clin Microbiol 2002; 40:2953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29018/abstract/86\">",
"      Pfaller MA, Espinel-Ingroff A, Jones RN. Clinical evaluation of the Sensititre YeastOne colorimetric antifungal plate for antifungal susceptibility testing of the new triazoles voriconazole, posaconazole, and ravuconazole. J Clin Microbiol 2004; 42:4577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29018/abstract/87\">",
"      Pfaller MA, Chaturvedi V, Diekema DJ, et al. Clinical evaluation of the Sensititre YeastOne colorimetric antifungal panel for antifungal susceptibility testing of the echinocandins anidulafungin, caspofungin, and micafungin. J Clin Microbiol 2008; 46:2155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29018/abstract/88\">",
"      Cuenca-Estrella M, Lee-Yang W, Ciblak MA, et al. Comparative evaluation of NCCLS M27-A and EUCAST broth microdilution procedures for antifungal susceptibility testing of candida species. Antimicrob Agents Chemother 2002; 46:3644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29018/abstract/89\">",
"      Espinel-Ingroff A, Barchiesi F, Cuenca-Estrella M, et al. International and multicenter comparison of EUCAST and CLSI M27-A2 broth microdilution methods for testing susceptibilities of Candida spp. to fluconazole, itraconazole, posaconazole, and voriconazole. J Clin Microbiol 2005; 43:3884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29018/abstract/90\">",
"      Cuenca-Estrella M, Moore CB, Barchiesi F, et al. Multicenter evaluation of the reproducibility of the proposed antifungal susceptibility testing method for fermentative yeasts of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antimicrobial Susceptibility Testing (AFST-EUCAST). Clin Microbiol Infect 2003; 9:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29018/abstract/91\">",
"      Pfaller MA, Diekema DJ, Procop GW, Rinaldi MG. Multicenter comparison of the VITEK 2 yeast susceptibility test with the CLSI broth microdilution reference method for testing fluconazole against Candida spp. J Clin Microbiol 2007; 45:796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29018/abstract/92\">",
"      Pfaller MA, Diekema DJ, Procop GW, Rinaldi MG. Multicenter comparison of the VITEK 2 antifungal susceptibility test with the CLSI broth microdilution reference method for testing amphotericin B, flucytosine, and voriconazole against Candida spp. J Clin Microbiol 2007; 45:3522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29018/abstract/93\">",
"      Aubertine CL, Rivera M, Rohan SM, Larone DH. Comparative study of the new colorimetric VITEK 2 yeast identification card versus the older fluorometric card and of CHROMagar Candida as a source medium with the new card. J Clin Microbiol 2006; 44:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29018/abstract/94\">",
"      Peterson JF, Pfaller MA, Diekema DJ, et al. Multicenter comparison of the Vitek 2 antifungal susceptibility test with the CLSI broth microdilution reference method for testing caspofungin, micafungin, and posaconazole against Candida spp. J Clin Microbiol 2011; 49:1765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29018/abstract/95\">",
"      Peterson LR, Shanholtzer CJ. Tests for bactericidal effects of antimicrobial agents: technical performance and clinical relevance. Clin Microbiol Rev 1992; 5:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29018/abstract/96\">",
"      Pfaller MA, Sheehan DJ, Rex JH. Determination of fungicidal activities against yeasts and molds: lessons learned from bactericidal testing and the need for standardization. Clin Microbiol Rev 2004; 17:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29018/abstract/97\">",
"      Stratton CW. Dead bugs don't mutate: susceptibility issues in the emergence of bacterial resistance. Emerg Infect Dis 2003; 9:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29018/abstract/98\">",
"      Espinel-Ingroff A. In vitro fungicidal activities of voriconazole, itraconazole, and amphotericin B against opportunistic moniliaceous and dematiaceous fungi. J Clin Microbiol 2001; 39:954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29018/abstract/99\">",
"      Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 48:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29018/abstract/100\">",
"      Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 2007; 20:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29018/abstract/101\">",
"      Pfaller MA, Diekema DJ, International Fungal Surveillance Participant Group. Twelve years of fluconazole in clinical practice: global trends in species distribution and fluconazole susceptibility of bloodstream isolates of Candida. Clin Microbiol Infect 2004; 10 Suppl 1:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29018/abstract/102\">",
"      Pfaller MA, Diekema DJ. Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus. J Clin Microbiol 2004; 42:4419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29018/abstract/103\">",
"      Pfaller MA, Boyken L, Hollis RJ, et al. In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance. J Clin Microbiol 2008; 46:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29018/abstract/104\">",
"      Sun HY, Singh N. Characterisation of breakthrough invasive mycoses in echinocandin recipients: an evidence-based review. Int J Antimicrob Agents 2010; 35:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29018/abstract/105\">",
"      Chapeland-Leclerc F, Hennequin C, Papon N, et al. Acquisition of flucytosine, azole, and caspofungin resistance in Candida glabrata bloodstream isolates serially obtained from a hematopoietic stem cell transplant recipient. Antimicrob Agents Chemother 2010; 54:1360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29018/abstract/106\">",
"      Dannaoui E, Desnos-Ollivier M, Garcia-Hermoso D, et al. Candida spp. with acquired echinocandin resistance, France, 2004-2010. Emerg Infect Dis 2012; 18:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29018/abstract/107\">",
"      Dodgson KJ, Dodgson AR, Pujol C, et al. Caspofungin resistant C. glabrata. Clin Microbiol Infect 2005; 11 (Suppl 2):364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29018/abstract/108\">",
"      Kofteridis DP, Lewis RE, Kontoyiannis DP. Caspofungin-non-susceptible Candida isolates in cancer patients. J Antimicrob Chemother 2010; 65:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29018/abstract/109\">",
"      Krogh-Madsen M, Arendrup MC, Heslet L, Knudsen JD. Amphotericin B and caspofungin resistance in Candida glabrata isolates recovered from a critically ill patient. Clin Infect Dis 2006; 42:938.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29018/abstract/110\">",
"      Pfaller MA, Castanheira M, Lockhart SR, et al. Frequency of decreased susceptibility and resistance to echinocandins among fluconazole-resistant bloodstream isolates of Candida glabrata. J Clin Microbiol 2012; 50:1199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29018/abstract/111\">",
"      Zimbeck AJ, Iqbal N, Ahlquist AM, et al. FKS mutations and elevated echinocandin MIC values among Candida glabrata isolates from U.S. population-based surveillance. Antimicrob Agents Chemother 2010; 54:5042.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29018/abstract/112\">",
"      Pfaller MA, Castanheira M, Lockhart SR, et al. Frequency of decreased susceptibility and resistance to echinocandins among fluconazole-resistant bloodstream isolates of Candida glabrata. J Clin Microbiol 2012; 50:1199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29018/abstract/113\">",
"      Pfaller MA, Messer SA, Boyken L, et al. In vitro activities of 5-fluorocytosine against 8,803 clinical isolates of Candida spp.: global assessment of primary resistance using National Committee for Clinical Laboratory Standards susceptibility testing methods. Antimicrob Agents Chemother 2002; 46:3518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29018/abstract/114\">",
"      Perlroth J, Choi B, Spellberg B. Nosocomial fungal infections: epidemiology, diagnosis, and treatment. Med Mycol 2007; 45:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29018/abstract/115\">",
"      Pfaller MA, Messer SA, Boyken L, et al. Global trends in the antifungal susceptibility of Cryptococcus neoformans (1990 to 2004). J Clin Microbiol 2005; 43:2163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29018/abstract/116\">",
"      Arikan S, Has&ccedil;elik G. Comparison of NCCLS microdilution method and Etest in antifungal susceptibility testing of clinical Trichosporon asahii isolates. Diagn Microbiol Infect Dis 2002; 43:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29018/abstract/117\">",
"      Paphitou NI, Ostrosky-Zeichner L, Paetznick VL, et al. In vitro antifungal susceptibilities of Trichosporon species. Antimicrob Agents Chemother 2002; 46:1144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29018/abstract/118\">",
"      Serena C, Pastor FJ, Ortoneda M, et al. In vitro antifungal susceptibilities of uncommon basidiomycetous yeasts. Antimicrob Agents Chemother 2004; 48:2724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29018/abstract/119\">",
"      Asada N, Uryu H, Koseki M, et al. Successful treatment of breakthrough Trichosporon asahii fungemia with voriconazole in a patient with acute myeloid leukemia. Clin Infect Dis 2006; 43:e39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29018/abstract/120\">",
"      Diekema DJ, Petroelje B, Messer SA, et al. Activities of available and investigational antifungal agents against rhodotorula species. J Clin Microbiol 2005; 43:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29018/abstract/121\">",
"      Zerva L, Hollis RJ, Pfaller MA. In vitro susceptibility testing and DNA typing of Saccharomyces cerevisiae clinical isolates. J Clin Microbiol 1996; 34:3031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29018/abstract/122\">",
"      Pfaller MA, Messer S, Jones RN. Activity of a new triazole, Sch 56592, compared with those of four other antifungal agents tested against clinical isolates of Candida spp. and Saccharomyces cerevisiae. Antimicrob Agents Chemother 1997; 41:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29018/abstract/123\">",
"      Swinne D, Watelle M, Nolard N. In vitro activities of voriconazole, fluconazole, itraconazole and amphotericin B against non Candida albicans yeast isolates. Rev Iberoam Micol 2005; 22:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29018/abstract/124\">",
"      Pfaller, MA, Diekema, DJ, Merz, WG. Infections due to emerging non-Candida, non-Cryptococcus opportunistic yeast pathogens. Curr Fungal Infect Reports 2007; 1:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29018/abstract/125\">",
"      Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008; 46:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29018/abstract/126\">",
"      Sabatelli F, Patel R, Mann PA, et al. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob Agents Chemother 2006; 50:2009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29018/abstract/127\">",
"      Cortez KJ, Roilides E, Quiroz-Telles F, et al. Infections caused by Scedosporium spp. Clin Microbiol Rev 2008; 21:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29018/abstract/128\">",
"      Pfaller, MA, Diekema, DJ. Azole antifungal drug cross-resistance: mechanisms, epidemiology, and clinical significance. J Invasive Fungal Infect 2007; 1:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29018/abstract/129\">",
"      Alexander BD, Schell WA, Miller JL, et al. Candida glabrata fungemia in transplant patients receiving voriconazole after fluconazole. Transplantation 2005; 80:868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29018/abstract/130\">",
"      Lupetti A, Danesi R, Campa M, et al. Molecular basis of resistance to azole antifungals. Trends Mol Med 2002; 8:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29018/abstract/131\">",
"      White TC, Marr KA, Bowden RA. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin Microbiol Rev 1998; 11:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29018/abstract/132\">",
"      Pfaller MA, Messer SA, Boyken L, et al. Selection of a surrogate agent (fluconazole or voriconazole) for initial susceptibility testing of posaconazole against Candida spp.: results from a global antifungal surveillance program. J Clin Microbiol 2008; 46:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29018/abstract/133\">",
"      Pfaller MA, Boyken L, Hollis RJ, et al. In vitro susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species to itraconazole: global survey of 9,359 isolates tested by clinical and laboratory standards institute broth microdilution methods. J Clin Microbiol 2005; 43:3807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29018/abstract/134\">",
"      Perlin DS. Resistance to echinocandin-class antifungal drugs. Drug Resist Updat 2007; 10:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/21/29018/abstract/135\">",
"      Mellado E, Garcia-Effron G, Alc&aacute;zar-Fuoli L, et al. A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations. Antimicrob Agents Chemother 2007; 51:1897.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 465 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-180.241.123.62-BF10BB01C4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_21_29018=[""].join("\n");
var outline_f28_21_29018=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H37\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Rationale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Limitations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Clinical relevance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Definitions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Minimum inhibitory concentration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Minimum effective concentration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H906841683\">",
"      - Clinical breakpoints",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1471001798\">",
"      - Epidemiologic cutoff values",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      INDICATIONS FOR TESTING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      STANDARDIZED METHODS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Broth dilution methods",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Yeasts",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Filamentous fungi",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Disk diffusion methods",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Yeasts",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Filamentous fungi",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      COMMERCIAL MIC METHODS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Etest",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Sensititre YeastOne panel",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      VITEK 2 Yeast Susceptibility Test",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      FUNGICIDAL ACTIVITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUSCEPTIBILITY PATTERNS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Candida spp",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Amphotericin B",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Azoles",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Echinocandins",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Flucytosine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Other yeasts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Molds",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      CROSS-RESISTANCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Candida spp",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      - Azoles",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      - Echinocandins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Filamentous fungi",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/465\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/465|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?3/16/3337\" title=\"picture 1\">",
"      Broth dilution test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/50/40736\" title=\"picture 2\">",
"      Disk diffusion test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?1/34/1574\" title=\"picture 3\">",
"      Fungal Etest",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/465|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/59/42941\" title=\"table 1\">",
"      Antifungal susceptibility testing indications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?25/10/25774\" title=\"table 2\">",
"      Clinical breakpoints for common Candida spp",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?37/33/38428\" title=\"table 3\">",
"      Candida spp susceptibility",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?35/44/36559\" title=\"table 4\">",
"      Candida spp MICs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?29/2/29742\" title=\"table 5\">",
"      MICs for other yeasts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?29/34/30254\" title=\"table 6\">",
"      Filamentous fungi MICs",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/46/6890?source=related_link\">",
"      Mucormycosis (zygomycosis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/18/6439?source=related_link\">",
"      Mycology, pathogenesis, and epidemiology of Fusarium infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/5/17495?source=related_link\">",
"      Overview of antibacterial susceptibility testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/41/15001?source=related_link\">",
"      Pharmacology of amphotericin B",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36938?source=related_link\">",
"      Pharmacology of azoles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/11/43190?source=related_link\">",
"      Pharmacology of flucytosine (5-FC)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/18/28970?source=related_link\">",
"      Treatment and prevention of invasive aspergillosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/13/29914?source=related_link\">",
"      Treatment of candidemia and invasive candidiasis in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_21_29019="Physical activity assessment in children";
var content_f28_21_29019=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F75838&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F75838&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Assessment of physical activity in children",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Sedentary behaviors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hours spent watching television, including videos or movies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hours spent playing video games (hand-held, internet or on-line, or television/video-based)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hours spent on computer or in internet-based activities, aside from school work",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hours spent talking on telephone or texting",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hours spent doing productive sedentary behaviors, such as homework, reading, and computer-based learning",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Physical activity behaviors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Type, frequency, duration, and intensity of structured physical activity (organized physical activity, such as sports)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Time spent in unstructured play (eg, outside play, and routine activity such as walking to school)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Example of questions to ask for a brief semi-quantitative assessment of physical activity in children. Evaluating activity in each of these areas provides an estimate of the child's overall activity level, and helps identify areas for potential improvement.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Based on recommendations in: Krebs NF, Himes JH, Jacobson D, Nicklas TA, Guilday P, Styne D. Assessment of child and adolescent overweight and obesity. Pediatrics 2007; 120 Suppl 4:S193-228.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_21_29019=[""].join("\n");
var outline_f28_21_29019=null;
var title_f28_21_29020="Drugs that cause seizures";
var content_f28_21_29020=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F54610&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F54610&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Drugs reported to potentially cause seizures or lower seizure threshold",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Psychotropic drugs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Tricyclic, tetracyclic antidepressants",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Serotonin reuptake inhibitors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Neuroleptic agents (phenothiazines, haloperiodol, clozapine)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Lithium",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Bupropion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Methylxanthines (theophylline)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Narcotic analgesics (meperidine, propoxyphene)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Antimicrobials",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Penicillins, cephalosporins in high dose",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Imipenem",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Isoniazid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Antimalarials",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Cyclosporine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Nalidixic acid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chemotherapeutic agents (methotrexate, chlorambucil)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        General anesthetics (ketamine, enflurane)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Local anesthetics (lidocaine - in toxic doses, disopyramide, bupivicaine)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stimulants (amphetamines, cocaine)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Antiarrhythmics (verapamil intoxication, mexiletine, procainamide, propranolol overdose)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Antihistamines (diphenydramine)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Baclofen",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Antiemetics (chlorpromazine)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     1. Olson, KR, Kearney, TE, Dyer JE, et al. Seizures associated with poisoning and drug overdose. Am J Emerg Med 1994; 12:392.",
"     <br>",
"      2. Shorvon, SD, Tallis, RC, Wallace, HK. Antiepileptic drugs: coprescription of proconvulsant drugs and oral contraceptives: a national study of antiepileptic drug prescribing practice. J Neurol Neurosurg Psychiatry 2002; 72:114.",
"      <br>",
"       3. Messing, RO, Closson, RG, Simon, RP. Drug-induced seizures: a 10-year experience. Neurology 1984; 34:1582.",
"       <br>",
"        4. Bey, TA, Walter, FJ. Seizures, in Ford: Clinical Toxicology, 1st ed., Copyright &copy; 2001 W. B. Saunders Company.",
"        <br>",
"         5. Gilmore, RL. Seizures associated with noneurologic medical conditions. In: The treatment of epilepsy: principles and practice, 3rd ed, Elaine Wyllie (Ed), Williams &amp; Wilkins, Baltimore 2001.",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_21_29020=[""].join("\n");
var outline_f28_21_29020=null;
var title_f28_21_29021="Lateral arteriogram SMA syn";
var content_f28_21_29021=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F61740&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F61740&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    A lateral arteriogram in a patient with SMA Syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 88px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The angle between the aorta (open arrowhead) and the SMA (closed arrowhead) is reduced causing compression of the third portion of the duodenum.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted from Ross J Bellavia, MD and Sheila Berlin, MD from Rainbow Babies and Children's Hospital in Cleveland, OH (uhrad.com). Reprinted with permission from Sheila Berlin, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_21_29021=[""].join("\n");
var outline_f28_21_29021=null;
var title_f28_21_29022="US smoking prevalence";
var content_f28_21_29022=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F59771&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F59771&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 544px\">",
"   <div class=\"ttl\">",
"    Prevalence of cigarette smoking in adults, by race and gender (United States, 1965 - 2000)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 524px; height: 283px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Data are age adjusted to the 2000 standard population. Survey redesigned in 1997 and data for 1998 and subsequent years may not be directly comparable to earlier years.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     National Health Interview Survey NHIS, NCHS, CDC",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_21_29022=[""].join("\n");
var outline_f28_21_29022=null;
var title_f28_21_29023="Pacemaker algorithm AV block";
var content_f28_21_29023=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F71370&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F71370&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 546px\">",
"   <div class=\"ttl\">",
"    Selection of pacemaker systems for patients with atrioventricular block",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 526px; height: 527px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Decisions are illustrated by diamonds. Shaded boxes indicate type of pacemaker.",
"    <div class=\"footnotes\">",
"     AV: atrioventricular.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Epstein AE, DiMarco JP, Ellenbogen KA, et al. ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2008; 51(21):e1-e62. Illustration used with permission of Elsevier Inc. All rights reserved. Copyright &copy; 2008 Elsevier Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_21_29023=[""].join("\n");
var outline_f28_21_29023=null;
